<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006921.pub2" GROUP_ID="MS" ID="926507050810293097" MERGED_FROM="" MODIFIED="2012-10-31 17:20:54 +0000" MODIFIED_BY="Liliana Coco" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.2" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2012-10-31 18:07:16 +0100" MODIFIED_BY="Liliana Coco">
<TITLE MODIFIED="2012-10-23 00:11:49 +0200" MODIFIED_BY="[Empty name]">Oral versus intravenous steroids for treatment of relapses in multiple sclerosis</TITLE>
<CONTACT>
<PERSON ID="6AA8E7BE82E26AA201AA8B4263EC858F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jodie</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Burton</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>jodie.burton@albertahealthservices.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+403 992-5311</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Neurosciences</DEPARTMENT>
<ORGANISATION>University of Calgary</ORGANISATION>
<ADDRESS_1>1403 29th St NW</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calgary</CITY>
<ZIP>T2N 2T9</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+403 943-3882</PHONE_1>
<PHONE_2/>
<FAX_1>+403 270-7162</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2012-10-31 18:07:16 +0100" MODIFIED_BY="Liliana Coco">
<PERSON ID="6AA8E7BE82E26AA201AA8B4263EC858F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jodie</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Burton</LAST_NAME>
<SUFFIX/>
<POSITION>Neurologist</POSITION>
<EMAIL_1>jodie.burton@albertahealthservices.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+403 992-5311</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Neurosciences</DEPARTMENT>
<ORGANISATION>University of Calgary</ORGANISATION>
<ADDRESS_1>1403 29th St NW</ADDRESS_1>
<ADDRESS_2/>
<CITY>Calgary</CITY>
<ZIP>T2N 2T9</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+403 943-3882</PHONE_1>
<PHONE_2/>
<FAX_1>+403 270-7162</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6AAEBF9782E26AA201AA8B42DE025251" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Paul</FIRST_NAME>
<MIDDLE_INITIALS>W</MIDDLE_INITIALS>
<LAST_NAME>O'Connor</LAST_NAME>
<SUFFIX/>
<POSITION>Division of Neurology, Head of Multiple Sclerosis Research</POSITION>
<EMAIL_1>oconnorp@smh.toronto.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Neurology</DEPARTMENT>
<ORGANISATION>St. Michael's Hospital</ORGANISATION>
<ADDRESS_1>30 Bond Street, 3rd Floor Shuter Wing, Room 3-007</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5B 1W8</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+416 864-5830</PHONE_1>
<PHONE_2/>
<FAX_1>+416 864-5147</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6AB28C6E82E26AA201AA8B426227CCBB" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Marika</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hohol</LAST_NAME>
<SUFFIX/>
<POSITION>Staff Neurologist, Adult Neurology Residency Program Director</POSITION>
<EMAIL_1>hoholm@smh.toronto.on.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Neurology</DEPARTMENT>
<ORGANISATION>St. Michael's Hospital</ORGANISATION>
<ADDRESS_1>943-55 Queen Street East</ADDRESS_1>
<ADDRESS_2/>
<CITY>Toronto</CITY>
<ZIP>M5C 1R6</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+416 864-5533</PHONE_1>
<PHONE_2/>
<FAX_1>+416 864-5610</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12175" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joseph</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Beyene</LAST_NAME>
<SUFFIX/>
<POSITION>Associate Professor</POSITION>
<EMAIL_1>beyene@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1280 Main Street West</ADDRESS_1>
<ADDRESS_2>MDCL 3208</ADDRESS_2>
<CITY>Hamilton</CITY>
<ZIP>L8S 4K1</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 905 525 9140 ext: 21333</PHONE_1>
<PHONE_2/>
<FAX_1>+1 905 528 2814</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-09-04 11:08:46 +0200" MODIFIED_BY="Liliana Coco">
<UP_TO_DATE>
<DATE DAY="13" MONTH="6" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="1" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="1" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2008"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2012-10-15 18:50:15 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-10-15 18:50:15 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="6" YEAR="2012"/>
<DESCRIPTION>
<P>One additional trial added in keeping with conclusions from original review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-06-18 11:58:55 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="1" YEAR="2012"/>
<DESCRIPTION>
<P>New search run: one trial added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-21 11:59:00 +0100" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Department of Health Policy, Management and Evaluation</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Division of Neurology, St. Michael's Hospital</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-31 18:10:43 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">A comparison of the efficacy of oral versus intravenous steroids in relapsing-remitting multiple sclerosis (RRMS)</TITLE>
<SUMMARY_BODY MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>RRMS is characterized by periods of disability (relapse) due to inflammation in the central nervous system. All research has shown that a "speeding up" of recovery is obtained by use of corticosteroids, given most often in intravenous form. If oral steroids worked as well as intravenous ones for relapse events, they would be easier to take and are more affordable.<BR/>
<BR/>The objective of this review was to assess if oral and intravenous steroids are equally effective and safe in aiding in the recovery from relapses. Among the pertinent literature, only five studies met the inclusion criteria, comprising a total of 215 participants. Despite some limitations in the methods used to conduct the studies (i.e. incomplete reporting of the participants who dropped out the studies and appropriateness of the sample size) and in the analysis of the data, all five studies found that there were no significant differences in term of benefits and adverse events and in the pharmacological and radiological outcomes in patients taking oral or intravenous steroids. Both treatments appear to be equally effective and safe. Based on this evidence, oral steroid therapy may be a practical and effective alternative to intravenous steroid therapy for the treatment of MS relapses.<BR/>
</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>This is an updated Cochrane review of the previous version published (Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.pub2).</P>
<P>Multiple sclerosis (MS), a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS), is characterized by recurrent relapses of CNS inflammation ranging from mild to severely disabling.  Relapses have long been treated with steroids to reduce inflammation and hasten recovery.  However, the commonly used intravenous methylprednisolone (IVMP) requires repeated infusions with the added costs of homecare or hospitalization, and may interfere with daily responsibilities. Oral steroids have been used in place of intravenous steroids, with lower direct and indirect costs.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The primary objective was to compare efficacy of oral versus intravenous steroids in promoting disability recovery in MS relapses &lt;= six weeks.  Secondary objectives included subsequent relapse rate, disability, ambulation, hospitalization, immunological markers, radiological markers, and quality of life.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-08-29 04:03:14 +0200" MODIFIED_BY="[Empty name]">
<P>A literature search was performed using Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group's Trials Register (January 2012), abstracts from meetings of the American Academy of Neurology (2008-2012), the European Federation of Neurological Sciences (2008-2012), the European Committee for Treatment and Research in Multiple Sclerosis and American Committee for Treatment and Research in Multiple Sclerosis (2008-2012) handsearching. No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Randomized or quasi-randomized trials comparing oral versus intravenous steroids for acute relapses (&lt;= six weeks) in patients with clinically definite MSover age 16 were eligible.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Three review authors (JB, PO and MH) participated in the independent assessment of all published articles as potentially relevant to the review. Any disagreement was resolved by discussion among review authors.</P>
<P>We contacted study authors for additional information.</P>
<P>Methodological quality was assessed by the same three review authors. Relevant data were extracted, and effect size was reported as mean difference (MD), mean difference (MD), odds ratio (OR) and absolute risk difference (ARD).</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>With this current update, a total of five eligible studies (215 patients) were identified. Only one outcome, the proportion of patients with Expanded Disability Status Scale (EDSS) improvement at four weeks, was common to three trials, while two trials examined magnetic resonance imaging (MRI) outcomes. The results of this review shows there is no significant difference in relapse recovery at week four (MD -0.22, 95% confidence interval (95% CI), 0.71 to 0.26, P = 0.20) nor differences in magnetic resonance imaging (MRI) gadolinium enhancement activity based on oral versus intravenous steroid treatment. However, only two of the five studies employed more current and rigorous methodological techniques, so these results must be taken with some caution. The Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA) trial and the "Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses" (COPOUSEP) trial, designed to address such limitations, are currently underway.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-08-29 04:03:56 +0200" MODIFIED_BY="[Empty name]">
<P>The analysis of the five included trials comparing intravenous versus oral steroid therapy for MS relapses do not demonstrate any significant differences in clinical (benefits and adverse events), radiological or pharmacological outcomes. Based on the evidence, oral steroid therapy may be a practical and effective alternative to intravenous steroid therapy in the treatment of MS relapses.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-26 10:56:34 +0200" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Liliana Coco">
<CONDITION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Multiple sclerosis (MS) is the most common neurodegenerative autoimmune disease in young adults in North America and Europe (<LINK REF="REF-Noseworthy-2000" TYPE="REFERENCE">Noseworthy 2000</LINK>). In the majority of patients, the hallmark of the disease is the relapse, defined as an episode of neurological dysfunction lasting &gt; 24 hours not in the context of fever and infection (<LINK REF="REF-Noseworthy-2000" TYPE="REFERENCE">Noseworthy 2000</LINK>). Clinical relapses are believed to be the result of demyelination, inflammation of the white matter in the central nervous system (CNS), with subsequent recovery and remyelination (<LINK REF="REF-Noseworthy-2000" TYPE="REFERENCE">Noseworthy 2000</LINK>). On average, a patient will experience one relapse every two years, and these events can range from extremely mild to significantly disabling, at times requiring hospitalization and supportive care (<LINK REF="REF-Confavreux-2006" TYPE="REFERENCE">Confavreux 2006</LINK>). Steroid preparations have been used to treat MS relapse events for over 50 years, with adrenocorticotrophin (ACTH) and cortisone being the common medications used at that time (<LINK REF="REF-Jonsson-1951" TYPE="REFERENCE">Jonsson 1951</LINK>; <LINK REF="STD-Tourtellotte-1965" TYPE="STUDY">Tourtellotte 1965</LINK> ). In recent years, methylprednisolone and prednisone have become the mainstay of relapse therapy.</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The vast majority of glucocorticoid activity in most mammals is from cortisol. The physiological actions of glucocorticoids occur in many cell types including hepatocytes, epithelial cells, neurons and immune cells. In these cell types, the glucocorticoid receptor regulates numerous genes that encode enzymes of carbohydrate and amino acid metabolism, hormones, hormone receptors, acute-phase proteins, antibacterial actions and serum proteins (<LINK REF="REF-Necela-2004" TYPE="REFERENCE">Necela 2004</LINK>). Glucocorticoid medications in demyelinating disease have multiple mechanisms of action in this context as well. Most of the cellular and physiological effects of glucocorticoids occur via the glucocorticoid receptor (one of a nuclear receptor superfamily) that impacts gene transcription and signaling (<LINK REF="REF-Schweingruber-2011" TYPE="REFERENCE">Schweingruber 2011</LINK>). Glucocorticoids will either interact with the membrane glucocorticoid receptor or cytosolic receptor. Binding in the cytosol allows the receptor to be released from heat shock proteins such that it is able to impact gene transcription. Another method by which glucocorticoids impact on gene transcription is their interaction with other transcription factors such as activating protein-1 (AP-1), nuclear factor kappa B (NfkB) and cAMP-responsive chemotaxis element binding protein (<LINK REF="REF-Andersson-1998" TYPE="REFERENCE">Andersson 1998</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Multiple sclerosis is a disease most associated with dysfunction in the inflammatory cascade, with a shift towards the pro-inflammatory or "Th1" state, and away from the anti-inflammatory of "Th2" state. Certain T-cell populations and cytokines highly complicit in disease immunopathology are significantly impacted by exogenous glucorticoid use. Steroids are postulated to positively impact on MS at the molecular level by many mechanisms including the reduction of adhesion molecule production (which is a step in leukocyte diapedesis) and protection of the blood brain barrier, the reduction of pro-inflammatory cytokine levels and circulating CD4 T-lymphocytes and B lymphocytes and apoptosis of certain T-cell subtypes (<LINK REF="REF-Andersson-1998" TYPE="REFERENCE">Andersson 1998</LINK>; <LINK REF="REF-Schweingruber-2011" TYPE="REFERENCE">Schweingruber 2011</LINK>). Specifically, glucorticoids suppress the production of such pro-inflammatory cytokines as interferon gamma, tumor necrosis factor alpha, IL-2 and IL-12 and also suppress nitric oxide synthesis while anti-inflammatory cytokines such as IL-4 and transforming growth factor beta are upregulated (<LINK REF="REF-Schweingruber-2011" TYPE="REFERENCE">Schweingruber 2011</LINK>). There is the perception that intravenous steroids work "faster" compared with oral preparations, although this has not been established (<LINK REF="REF-Tremlett-1998" TYPE="REFERENCE">Tremlett 1998</LINK>). However, the efficacy of steroids versus placebo, specifically ACTH and intravenous methylprednisolone (IVMP), in reducing short-term disability associated with relapse events, has been established in a recent Cochrane review involving 377 participants (<LINK REF="REF-Filippini-2000" TYPE="REFERENCE">Filippini 2000</LINK>). Steroid therapy also presents the risk of numerous adverse events, ranging from mild to life-threatening. Such adverse events include weight gain and edema, sleep and mood disturbance including depression and psychosis, myopathy, cataracts, osteoporosis, hypertension, impaired glucose tolerance, gastrointestinal dysfunction, pancreatitis and vascular necrosis, although such outcomes are more typical in long-term steroid therapy (<LINK REF="REF-Andersson-1998" TYPE="REFERENCE">Andersson 1998</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>While intravenous steroid therapy has been proven to be efficacious in hastening relapse recovery, it can be a cumbersome and costly treatment. A cost analysis in a major Canadian hospital in 1994-1995 demonstrated that the cost, on average, for a four-day IVMP treatment regimen was approximately $1,110 Canadian for inpatients and $700 for outpatients (<LINK REF="REF-Robson-1998" TYPE="REFERENCE">Robson 1998</LINK>). A more recent review of relapse treatment costs in the United States revealed that the cost of setting up a single dose of IVMP is roughly $99, with homecare visitation for a four-day course of this therapy costing approximately $3,800 per patient (<LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>). Hospitalization for treatment increases the cost several fold (<LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>). Additionally, there are indirect costs associated with intravenous therapy, including lost productivity and work-force related costs, potential discomfort, risk of complications with intravenous placement, and the stigma of appearing ill or disabled.</P>
<P>Orally administered steroid use is less expensive, and less demanding on healthcare resources and patients compared with intravenous regimens (<LINK REF="REF-O_x0027_Brien-2003" TYPE="REFERENCE">O'Brien 2003</LINK>). Evidence from randomized trials of oral corticosteroids versus placebo in MS relapses (<LINK REF="STD-Sellebjerg-1998" TYPE="STUDY">Sellebjerg 1998</LINK>) and clinically isolated optic neuritis (<LINK REF="STD-Sellebjerg-1999" TYPE="STUDY">Sellebjerg 1999</LINK>) have shown that 500 mg of oral methylprednisolone (oral MP) for five days is significantly more effective than placebo in promoting neurological recovery as early as three weeks, with a reduction in pro-inflammatory immunological markers in cerebrospinal fluid (CSF) (<LINK REF="REF-Sellebjerg-2000" TYPE="REFERENCE">Sellebjerg 2000</LINK>). Troiano 1985 (<LINK REF="REF-Troiano-1985" TYPE="REFERENCE">Troiano 1985</LINK>) demonstrated that higher doses of prednisone (60-120 mg daily) versus lower doses (50-100 mg alternating days) for a minimum of one week had fewer gadolinium enhancing lesions on magnetic resonance imaging (MRI) performed an average of five weeks after relapse onset, although the trial was neither controlled nor blinded. While there are trials that support the superiority of oral steroids over placebo for treating MS relapses, the evidence for their use is limited in comparison to the evidence for intravenous steroids in this context (<LINK REF="REF-Filippini-2000" TYPE="REFERENCE">Filippini 2000</LINK>), although one meta-analysis of steroids in MS and optic neuritis included four studies of oral steroid therapy out of a total of 12 trials, all placebo-controlled (<LINK REF="REF-Brusaferri-2000" TYPE="REFERENCE">Brusaferri 2000</LINK>). In this study, subgroup analysis was not performed on oral steroids as they were taken to be equivalent to other regimens based on pharmacological equivalence calculations. Comparisons were made between low- versus high-dose regimens however, of which only one oral trial was considered high-dose, therefore dose, not route, may have been the more important variable (<LINK REF="REF-Brusaferri-2000" TYPE="REFERENCE">Brusaferri 2000</LINK>). While there are several publications touting the equivalency of oral and intravenous steroids in MS care, concluding that these therapies are equivalent based on trials that do not compare these agents is methodologically unacceptable</P>
<P>If oral steroids prove to be a viable replacement for intravenous steroids in relapse treatment, they could be taken at the patient's convenience with discretion, and could potentially minimize lost productivity and other indirect costs. It is therefore necessary to determine the efficacy and safety of oral steroid preparations compared with their intravenous counterparts in a systematic and methodologically rigorous fashion .</P>
<P>This is an update of a Cochrane review first published in 2009 which aims to evaluate the efficacy and safety of this treatment (Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No.: CD006921. DOI: 10.1002/14651858.CD006921.pub2).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The objective of this review is to test the hypothesis that intravenous steroid treatment and oral steroid treatment in the context of acute MS relapses are equally efficacious and safe. The main objective is to determine if there is a difference in efficacy with respect to the degree of disability recovery between oral versus intravenous steroid treatment given at the time of relapse in patients with a diagnosis of MS.<BR/>
</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2012-08-29 04:04:18 +0200" MODIFIED_BY="[Empty name]">
<P>Only randomized and quasi-randomized trials were considered for this review. As well, trials had to be designed to directly compare efficacy (e.g. clinical, biochemical, pharmacological, immunological, radiological, cost effectiveness) or safety outcomes between oral versus intravenous steroid treatments given at the time of an acute MS relapse </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Participants in eligible trials must have had a diagnosis of clinically definite relapsing (relapsing-remitting (RR) or relapsing-progressive (RP) MS based on the accepted criteria at the time of the study (<LINK REF="REF-Schumacher-1965" TYPE="REFERENCE">Schumacher 1965</LINK>; <LINK REF="REF-Poser-1983" TYPE="REFERENCE">Poser 1983</LINK>; <LINK REF="REF-McDonald-2001" TYPE="REFERENCE">McDonald 2001</LINK>; <LINK REF="REF-Polman-2005" TYPE="REFERENCE">Polman 2005</LINK>) with an acute relapse event. Patients had to be 16 years or older, and have experienced a relapse event felt to merit steroid therapy. Patients must have received treatment within 30 days of the onset of the event. Patients also must have had their first "post-treatment" reassessment of neurological disability status for the study relapse event within six weeks. Relapse was defined as an episode of neurological dysfunction lasting &gt;24 hours not in the context of fever and infection (<LINK REF="REF-Noseworthy-2000" TYPE="REFERENCE">Noseworthy 2000</LINK>). However, other definitions were accepted at the review authors' discretion.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The two therapies compared in this review were any intravenous form of a steroid compared with any oral form of steroid. As there is no standard form of oral steroid therapy for MS relapse events, there was no restriction on form or dose. Typically, corticosteroids have been used, including oral prednisone, methylprednisolone and prednisolone. Intravenous steroid type and dose was also not restricted, although at the present time, the most common intravenous form of steroid therapy in MS by far is methylprednisolone.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Trials with at least one of the following outcome comparisons between oral and intravenous steroid groups were evaluated. The following is a list of outcomes (primary and secondary) and the headings under which they fall.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Liliana Coco">
<P>The degree of recovery from relapse at &lt; six weeks as measured by the mean change in Kurtzke's Expanded Disability Status Scale (EDSS) (<LINK REF="REF-Kurtzke-1983" TYPE="REFERENCE">Kurtzke 1983</LINK>).</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Liliana Coco">
<SUBSECTION>
<HEADING LEVEL="5">Relapse Recovery</HEADING>
<OL>
<LI>The degree of recovery from relapse at &lt; six weeks as measured by mean change in the Multiple Sclerosis Functional Composite (MSFC), a single composite score computed from scores on tasks for cognition, arm function and ambulation (<LINK REF="REF-Fisher-1999" TYPE="REFERENCE">Fisher 1999</LINK>).</LI>
<LI>The proportion of patients with improvement from the relapse event &lt; six weeks.</LI>
<LI>The proportion of patients requiring re treatment in the oral versus intravenous group.</LI>
<LI>The mean change in Ambulation Index between groups &lt; six weeks.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subsequent Relapses and Disability Status</HEADING>
<OL>
<LI>Relapse rate following treatment, measured as the mean annualized relapse rate.</LI>
<LI>Time to next relapse measured in days.</LI>
<LI>Long-term disability status measured as mean change in EDSS at a minimum of six months (<LINK REF="REF-Rio-2006" TYPE="REFERENCE">Rio 2006</LINK>).</LI>
<LI>Proportion relapse-free patients at a minimum of one1 month with no maximum limit.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pharmacological Efficacy</HEADING>
<OL>
<LI>Bioavailability measured as mean serum concentration and mean area under the curve.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Immunological Markers of Disease Status</HEADING>
<OL>
<LI>Immunological markers assessed by measuring the change of mean titers of cytokines and matrix-metalloproteinases (MMPs) in serum and CSF.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Radiological Efficacy</HEADING>
<OL>
<LI>Magnetic resonance imaging (MRI) response measured by mean change and volume of gadolinium enhancing lesions and T2 lesion count and volume and mean new number of gadolinium and T2 lesions.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse Events</HEADING>
<OL>
<LI>Proportion with the following non-serious adverse events.</LI>
<UL>
<LI>Weight gain/edema</LI>
<LI>Insomnia</LI>
<LI>Mood disturbance</LI>
<LI>Nausea/vomiting</LI>
<LI>Dyspepsia</LI>
<LI>Headache</LI>
<LI>Hyperglycemia (transient)</LI>
<LI>Flushing</LI>
<LI>Myopathy</LI>
</UL>
<LI>Proportion with the following serious adverse events.</LI>
<UL>
<LI>Pancreatitis</LI>
<LI>Diabetes</LI>
<LI>Cataracts</LI>
<LI>Bone density changes/osteoporosis</LI>
<LI>Avascular necrosis</LI>
<LI>Non-traumatic fractures</LI>
<LI>Adrenal insufficiency</LI>
<LI>Myopathy</LI>
<LI>Infection</LI>
</UL>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Direct and Indirect Costs</HEADING>
<OL>
<LI>Mean monetary costs associated with medications, homecare services, hospital stay and consultations.</LI>
<LI>Mean monetary costs of lost work productivity.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Hospitalization</HEADING>
<OL>
<LI>The mean length-of-stay in days for hospital for relapse and/or treatment.</LI>
<LI>The proportion requiring hospitalization for relapse and/or treatment.</LI>
</OL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of Life</HEADING>
<OL>
<LI>Quality of life measured as mean change in validated scales that are both specific to MS and disease in general as per the patient and family/proxy.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>All publications describing randomized controlled trials of a direct comparison of oral versus intravenous steroid preparations given at the time of an acute MS relapse were sought. </P>
<ELECTRONIC_SEARCHES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Electronic searches were performed by review author JB and the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Working Group on using the Cochrane MS Group Trials Register (2008-January 2012) which among other sources, contains CENTRAL, MEDLINE, EMBASE, CINAHL, LILACS, PEDRO.</P>
<P>The search terms are listed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>
</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Liliana Coco">
<P>Handsearching was performed using the guidelines of the Cochrane Multiple Sclerosis Working Group (described in the "Search Strategies for identification of studies") section within the editorial information pertaining to the Cochrane Multiple Sclerosis Working Group in <I>The Cochrane Library</I>. We also handsearched cited trials in review papers and reference lists, conference proceedings, dissertations and abstracts where appropriate. Specifically, we searched abstracts from the annual meetings of the American Academy of Neurology (2008-2012), the European Federation of Neurological Sciences (2008-2012), the European Committee for Treatment and Research in Multiple Sclerosis (2008-2012) and the American Committee for Treatment and Research in Multiple Sclerosis (2008-2012). Additional data were sought by reviewing trials listed in registries and contacting study authors and investigators as necessary (<A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A>).</P>
<P>There was no restriction on language. Letters, reviews, editorials and commentaries not containing original data were excluded.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>
<BR/>
</B>
</P>
<STUDY_SELECTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Three review authors (JB, PO and MH) participated in the independent assessment of all published articles as potentially relevant to the review. In order to be eligible for inclusion in the review, a trial must have met the following criteria.</P>
<UL>
<LI>The study population was &gt;= 16 years of age.</LI>
<LI>The trial compared outcomes of oral steroid preparations directly to intravenous steroid preparations.;</LI>
<LI>The intervention was in the context of an acute MS relapse.</LI>
<LI>The intervention was offered within 30 days of the onset of the relapse event.</LI>
<LI>The first assessment of response with respect to the relapse event occurred within six weeks of treatment.</LI>
<LI>The trial was randomized or quasi-randomized.</LI>
<LI>The trial used the EDSS or MSFC clinical scales to measure outcomes of disability.</LI>
</UL>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Two review authors (JB, and PO) independently extracted the data using standardized data collection forms. In keeping with an "intention-to-treat" analysis, whenever possible, the total number of patients assigned to each group was identified and noted, regardless of compliance, whether or not they received treatment, or were otherwise excluded from the originally published trial analysis. For continuous outcomes, mean and standard deviation, and the number in whom the outcome was observed, were extracted. For binary outcomes, the number of patients and the number of events within each group were extracted. When complete patient data were not available, we contacted the primary author or principal investigator of the trial requesting the data.<BR/>
</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Methodological quality was assessed by two review authors (JB and PO) following the domain-based evaluation described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> 5.0 (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>)</P>
<P>The following domains were assessed as 'Yes' (i.e. low risk of bias), 'Unclear' (uncertain risk of bias) or 'No' (i.e. high risk of bias):</P>
<UL>
<LI>sequence generation;</LI>
<LI>allocation concealment;</LI>
<LI>blinding (of participants, personnel and outcome assessors);</LI>
<LI>incomplete outcome data and use of intention-to-treat analyses;</LI>
<LI>selective outcome reporting.</LI>
<LI>rationale for sample size</LI>
<LI>use of non-inferiority design and methods</LI>
</UL>
<P>The review authors reported on each of these assessments in the 'Risk of bias in included studies' table.</P>
<P>Disagreements between review authors were resolved with the third author acting as an arbiter.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>SAS 9.3.1 (SAS Institute Inc., Casey, N.C.) was used to generate descriptive statistics for raw data when necessary, and RevMan 5 was used for all statistical analyses. Statistical parameters included odds ratio (OR), absolute risk difference (ARD), number needed to treat to benefit (NNTB), number needed to treat to harm (NNTH), mean difference (MD) and standardized mean difference (SMD) as appropriate. Ninety-five percent confidence intervals (CI) were reported for parameters of treatment effects.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-07-08 21:38:06 +0200" MODIFIED_BY="[Empty name]">
<P>Slight differences in the unit of measurement (e.g. EDSS versus MSFC) were given their own analysis. When possible, units were converted to those specified a priori for this review.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Imputation was planned to address missing data, however, two trials with missing data no longer had raw data available to assess, and the third trial had data missing for only two of 80 patients.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Tests of heterogeneity for between study differences were undertaken including calculating the Q and I<SUP>2</SUP> values to determine the appropriateness of combining studies. If there was significant heterogeneity, defined by the Cochrane Multiple Sclerosis Working Group as an I<SUP>2</SUP> &gt; 50% (<LINK REF="REF-D_x0027_Amico-2007" TYPE="REFERENCE">D'Amico 2007</LINK>), we used a random-effects model. If heterogeneity was not significant, we used a fixed-effect model for meta-analyses. If a meta-analysis was not possible, a qualitative review of the trials was undertaken.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-07-08 21:35:21 +0200" MODIFIED_BY="[Empty name]">
<P>A funnel plot to determine if publication biased was present was planned, but there was no evidence that trials eligible for inclusion in this review went unpublished.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Outcomes of interest in this review include continuous and dichotomous measures. Continuous outcomes were analyzed by calculating MD between groups, while dichotomous analyses were analyzed by ORs and RD to compare groups. A random-effects model was used for this meta-analysis. In this conservative model, the assumption is that while intervention effects are related between studies, there are still inherent differences in outcomes and studies, and so an adjustment in the weighting of the study contribution is made based on the variation or heterogeneity among intervention effects (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-07-08 21:35:02 +0200" MODIFIED_BY="[Empty name]">
<P>Additional pre-specified subgroup analyses for steroid type used, age, baseline EDSS, time to treatment, relapse type (optic neuritis, brainstem event, myelopathy or "other") and prior annualized relapse rate were chosen a priori to explain significant heterogeneity if indicated.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-09-04 11:33:33 +0200" MODIFIED_BY="[Empty name]">
<P>If the data supported it, sensitivity analyses (e.g. types of relapses, different forms of steroids within the oral or intravenous domains) were to be performed, however, it was determined that there was not a significant degree of variation in trial design or methodology to support such analyses in the eligible and included trials.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-26 10:56:34 +0200" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>See <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>, <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The above strategies, including the present update (January 2012), yielded a total of 709 articles, (630 references identified through the previous search and 79 by the new search) four abstracts and seven listings on clinicaltrials.gov (see table "Results of Literature Search for Eligible Trials") (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). See details of the trial detection and process selection in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>The original and updated search yielded 35 articles, four abstracts and three clinicaltrials.gov listings initially selected for further assessment, based on which a total of five trials (with two additional papers reporting additional outcomes from one of these trials) were eligible for inclusion while the remaining trials were excluded (see Table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details). Four of these trials were found in the original review, and one new trial was included based on this update (see <LINK TAG="INCLUDED_STUDIES_DESCR" TYPE="SECTION">Included studies</LINK>). These five eligible trials included a total of 215 patients including withdrawals and drop-outs. Clinical details regarding the participants, interventions and outcomes are given in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>Two of the identified trials for assessment are ongoing (<LINK REF="STD-OMEGA-2007" TYPE="STUDY">OMEGA 2007</LINK>; <LINK REF="STD-COPOUSEP-2009" TYPE="STUDY">COPOUSEP 2009</LINK>) and when results become available, they will be included in this review's subsequent update.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Treatment Regimens and Settings</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>, <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> used oral methylprednisolone ( oral MP) versus intravenous methylprednisolone (IVMP) for the two patient groups compared. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> used equivalent doses of 500 mg per day for a total of three days. The oral MP group received sham IV solution and the IVMP group received sham tablets. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> also used equivalent dosing, with 1000 mg of oral MP or IVMP for a total of five days while <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> used 1000 mg IVMP versus 1250 mg of oral MP for three days. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> had groups receive significantly non-equivalent dosing. The oral MP group received 48 mg once daily for seven days, then 24 mg once daily for seven days and finally 12 mg once daily for seven days. The IVMP group received 1000 mg of methylprednisolone intravenously once daily for three consecutive days, Sham oral and intravenous interventions were used for blinding as well. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> had groups receive either one dose of 1250 mg of oral prednisone or one gram of IVMP. Oral prednisone was given as 25- 50 mg-tablets and the IVMP was given in 100 mL normal saline infused over one hour. No sham interventions were used. This study was performed at an outpatient MS clinic. All trials appear to have been performed in the outpatient setting of a hospital-based MS care center.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Countries in Which the Studies were Conducted</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> and <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> were both performed in the United Kingdom. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> was performed in Italy, <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> was performed in Alberta, Canada and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> was performed in Spain.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Duration of Trials</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> enrolled patiens who had experienced a relapse within the previous 28 days, treated over three days, and were evaluated at baseline, day five and day 28 following treatment. Patients were scored by a "blind" assessor using the EDSS score at baseline, and again at five and 28 days following treatment. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> enrolled patients within 14 days of their relapse event and evaluated MRI and clinical outcomes over a 28-day period as well. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> also enrolled patients who had experienced a relapse within the previous 28 days. Patients in the oral MP group were treated for 21 days while the IVMP group received treatment over five days. Patients were evaluated at enrollment, weeks one, four and 12. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> treated patients with a single dose of medication and evaluated gastric tolerance over the following 48 hours. The duration between relapse and treatment was not published, but additional data provided showed that some patients in fact were treated outside of the six-week window, but given the fact that this would not impact on gastric tolerance measures, the trial was still included. <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> enrolled patients within 15 days of a relapse and monitored their response to treatment (three days) for the following 28 days, evaluating them at baseline, weeks one, four, 12 and 28 (unpublished data provided up to week 12 at the time it was solicited)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Participants</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> enrolled 38 patients (mean age 41.5 years) with clinically definite MS with a mean disease duration of 5.4 years, and a sex ratio of 26 women to nine men. Twenty patients received IVMP and 18 received oral MP. Thirty-five patients completed the trial and three drop-outs were not included in the final analysis. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> enrolled 40 patients (20 per group with clinically definite MS (mean age 36 years in the oral MP group and 31 years in the IVMP group) with a sex ratio of 14 women to six men in each group. Mean disease duration was 10 years in the oral MP group and seven years in the IVMP group. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> enrolled 80 adults (mean age 37 years in the IVMP group and 38 years in the oral MP group) with clinically definite MS and a sex ratio of 51 women to 49 men. Thirty-eight patients received IVMP and 42 received oral MP. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> enrolled 16 adults with MS with a mean age of 39 years, a mean disease duration of 5.7 years and a mean EDSS of 4.0. Eight patients were randomized to each of the two groups. The sex ratio was 13 women to four men. <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> enrolled 48 adults with MS and a mean age of 38 years and a sex ratio 40 women to eight men. of See Table "Characteristics of Included Studies" for details.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Types of comparisons</HEADING>
<P>Only the comparison of oral versus intravenous steroids was reviewed. Four of five trials (<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>; <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>; <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>; <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>) used methylprednisolone in both groups, while the fifth, <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK>, compared IVMP with prednisone.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-09-04 11:34:00 +0200" MODIFIED_BY="[Empty name]">
<P>The most common reasons for exclusion were: absence of an active comparator group, lack of randomization, or one of the two agents being compared not being oral. See Table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> .</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-10-26 10:56:01 +0200" MODIFIED_BY="[Empty name]">
<P>The information was extracted from the published papers and from data obtained by contacting the primary authors. See Table 1 <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> ('Risk of bias' summary) for further details. Disagreements between review authors were resolved with the third author acting as an arbiter.</P>
<ALLOCATION MODIFIED="2012-10-26 10:55:45 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Randomization methods and concealment of allocation</HEADING>
<P>All five trials (<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>; <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>; <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK>; <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>; <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>) were randomized. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> clearly documented the method of randomization and provided clear evidence of concealment of allocation. Specifically, patients were randomized through the hospital pharmacy according to a list of trial codes and medications provided in sealed envelopes, with randomization codes generated by a random number generator in blocks of four. This trial was given a grade of low risk of bias. As well, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>, and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>used appropriate randomization techniques thus both also received a low risk of bias score. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> and <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> however did not clearly indicate methods used for randomization, and so they both received a score of unclear risk of bias for randomizaiton.</P>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> also clearly specified concealment of allocation/masking of intervention (low risk of bias) while such methods were not clear for <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> or <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> (unclear risk of bias). <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> did not appear to utilize concealment of allocation and thus received a grade of high risk of bias</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2012-10-26 10:55:52 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Blinding of participants and assessors and tests of blinding</HEADING>
<P>Three of the five trials (<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>; <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>; <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>) were double-blinded and used sham interventions, and were all given a grade of low risk of bias. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> also reported on testing of blinding by having both the physicians and the patients guess their group assignment with results no better than by chance in both groups. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> employed blinding of the evaluating physicians and radiologists, but not of patients or treating physicians, and was given a grade of unclear bias. Contact with the authors of <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> revealed that blinding was used only in those performing laboratory analyses, with no apparent blinding of clinical evaluators or patients, and was given a grade of unclear bias, although the primary pharmacological outcome was presumably not vulnerable to bias.</P>
</SUBSECTION>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew and ability to perform intention-to-treat (ITT) analysis</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>, <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> all provided clear data about the number and nature of withdrawals. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> included a clear flow-chart to detail this aspect of the study, and thus these three trials received a grade of low risk of bias and ITT analysis was possible. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> was however was graded as unclear risk of bias based on a lack of detail about patient losses. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> did not appear to have any withdrawals or drop-outs based on the published trial, but a review of the data clearly shows an additional patient not mentioned in the publication. It was therefore graded as unclear risk of bias.</P>
</SUBSECTION>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-10-26 10:55:57 +0200" MODIFIED_BY="[Empty name]">
<P>While there did not appear to be evidence of intentional selective reporting in any of the five trials, there were some instances of missing a priori identified endpoints.</P>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> presented a significant challenge for analysis with published data. In this trial, the primary endpoint was reported to be the proportion of participants who improved by a minimum of one1 EDSS point at 28 days, although this value never appeared in the results or elsewhere in the manuscript. Furthermore, medians and interquartile ranges were presented for four different time periods, but the comparison of groups employed adjusted mean values. As well, in <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, while adverse events were reported to be minor, there was no detailed information supplied. Therefore <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> received a score of unclear risk for selective reporting. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> did not report the results at day five, nor the standard deviations or confidence intervals for post-treatment values at day 28. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> also reported that no significant adverse events occurred, but there was no further detail available on this measure in this trial. Therefore, <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> also received a grade of unclear risk of bias for selective reporting. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> included all patients in the final analysis with clear documentation of all planned outcomes, thus they both received a grade of low risk of bias for selective reporting. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> provided bar graphs and P values in the original publication but no data values for outcomes and therefore the published data presented an unclear risk of bias for selective reporting, however, the supervising author forwarded the appropriate data set for analysis.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-10-26 10:56:01 +0200" MODIFIED_BY="[Empty name]">
<P>Other statistical and design methodology was assessed for potential bias.</P>
<SUBSECTION>
<HEADING LEVEL="5">Rationale for sample size</HEADING>
<P>All trials documented the statistical rationale behind the sample size chosen. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, using a previous trial's results and standard deviation, calculated that a sample size of 38 participants per arm, using a two-tailed analysis with alpha of 0.05, would have a power of 90% and thus provides a low risk of bias. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> reported that based on previous trials, their sample size calculations had the power to detect a 25% difference in disability grade improvement between groups, however, the actual value of 1-ß is not indicated making risk of bias unclear. In <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>, the sample size was estimated to guarantee a power of 80% to demonstrate non-inferiority; with the assumption that IVMP was able to reduce by 90% the number of enhancing lesions detected during a relapse, and with a non-inferiority margin as a percentage reduction of 20%, and so it received a low risk of bias grade. <LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> has a high risk of bias having reported that the trial did not have a sample size that was appropriate to test bioequivalence between oral and intravenous steroids of 20%, but the data generated would allow for estimating sample sizes, presumably in future trials. <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> calculated that 22 patients per group were required for a power of 0.80 to reject the null hypothesis of the absence of non-inferiority (with a non-inferiority margin of one EDSS scale point and assuming a standard deviation of 1.13 and a significance level of 2.5% (CI 97.5%, unilateral) and therefore, has a low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Use of non-inferiority design and analysis methods</HEADING>
<P>
<LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> used an equivalence design an their study clearly indicates the range and confidence interval a priori, thus receiving a grade of low risk of bias. <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> also reported using a non-inferiority design indicating a non-inferiority margin of one EDSS point and a significance level of 2.5% (CI 97.5%). Despite this, in the data and analyses provided by <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>, the reporting of results did not conform to this design (however, these data are not formally published) such that the risk of bias is unclear. None of the remaining three trials employed this methodology although the rationale behind all three trials was clearly to show bioequivalence and/or non-inferiority and therefore have a high risk of bias in this category. This has significant implications for sample size and effect estimates, as well as interpretation of results. However, at the time, the understanding of equivalence trial methodology might not have been common-place.</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-26 10:56:34 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 1: Relapse recovery in first six weeks:</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Degree of MS relapse recovery with steroid treatment as change in Expanded Disability Status Scale (EDSS) at one week</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> measured EDSS at five days following treatment, but the data were not available. <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> reported clinical outcomes in the first week of treatment in a total of 168 patients with a mean difference (MD) for change in EDSS between groups at one week of -0.05 (95% confidence interval (CI) -0.38 to 0.28), which is not statistically significant.</P>
<P>
<I>Outcome 02 - Degree of MS relapse recovery with steroid treatment as change in EDSS at four weeks</I>
</P>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>, <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> all reported the change in EDSS four weeks after treatment with either IVMP or oral steroid therapy. <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> used equivalent doses of intravenous and oral MP (500 mg once daily for three days) while <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> used 500 mg once daily of IVMP for three days versus oral MP at 48 mg once daily for seven days, then 24 mg once daily for seven days and finally 12 mg once daily for seven days. Unfortunately, <LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK> could not be included in the pooled analysis secondary to an absence of required data (standard error information), although there was a statistically significant reduction in EDSS from pre-treatment to that time in both groups (4.85 to 3.5 in the IVMP group and 4.80 to 3.67 in the oral MP group) with no statistically significant difference in the magnitude of this improvement between groups. The pooled analysis of <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> (165 patients total) resulted in a MD change in EDSS between groups at four weeks of -0.22 (95% CI -0.71 to 0.26), again, not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 2: Proportion of patients with relapse recovery with steroid treatment at four weeks</HEADING>
<P>
<LINK REF="STD-Alam-1993" TYPE="STUDY">Alam 1993</LINK>, <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> all reported the proportion of patients experiencing improvement in EDSS and relapse recovery after steroid treatment in a total of 200 patients. The odds ratio (OR) of improvement with oral MP versus IVMP was 0.60 (95% CI 0.28 to 1.26) which is not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Relapse recovery as measured by the Multiple Sclerosis Functional Composite (MSFC)</HEADING>
<P>The eligible trials did not include this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Patients requiring additional courses of treatment for original relapse</HEADING>
<P>The eligible trials did not include this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 3: Change in Ambulation Index in first six weeks</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Mean change in Ambulation Index at week one</HEADING>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> reported the mean change in Ambulation Index between groups at week one was 0.00 (95% CI -0.39 to 0.39).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 02 - Mean change in Ambulation Index at week four</HEADING>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> reported the mean change in Ambulation Index between groups at week four was 0.40 (95% CI -0.11 to 0.91), which was not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 4: Long-term relapse rate following treatment</HEADING>
<P>Sharrack 2000 (patient group from <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>) analyzed relapse rate at six months, one year and two years following intervention.</P>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Relapse rate at six months post-treatment</HEADING>
<P>The relapse rate in the oral MP group at six months was 0.55 (0.74) compared with 0.34 (0.48) in the IVMP group for a MD of 0.21 (95% CI -0.06 to 0.48) which was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 02 - Relapse rate at year one post-treatment</HEADING>
<P>The relapse rate in the oral MP group at one year was 1.26 (1.31) compared with 0.92 (0.78) in the IVMP group for a MD of 0.34 (95% CI -0.13 to 0.81) which was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 03 - Relapse rate at year two post-treatment</HEADING>
<P>The relapse rate in the oral MP group in the second year was 0.86 (0.90) compared with 0.65 (0.79) in the IVMP group for a MD of 0.21 (95% CI -0.16 to 0.58) which was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 04 - Overall relapse for two-year period post-treatment</HEADING>
<P>The overall annualized relapse rate for the two-year period in the oral MP group was 1.06 (0.98) compared with 0.78 (0.65) in the IVMP group for a MD of 0.28 (95% CI -0.08 to 0.64) which was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 05 - Proportion of patients relapse-free at two years post-treatment</HEADING>
<P>Ten of 42 patients in the oral MP group compared with 11/38 patients in the IVMP group were relapse-free at two years post-treatment for an OR of 0.77 (95% CI 0.28 to 2.08) and an absolute risk difference (ARD) -0.05 (95% CI -0.24 to 0.14). These results are not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 5: Days to next relapse after treatment with steroids</HEADING>
<P>Sharrack 2000 (based on <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>) measured the EDSS at the time of first relapse subsequent to the steroid treatment in <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, with a MD between oral and IVMP groups of -47 days (95% CI -150.53 to 56.53), which is not statistically significant but the trend favors the oral group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 6: EDSS at first relapse after treatment with oral versus intravenous steroids</HEADING>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> found the mean EDSS at the time of the next relapse following the study relapse was 1.56 in the oral MP group and 1.53 in the IVMP group for a MD of 0.03 (95% CI -0.47 to 0.53) which is not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 7: Proportion of patients hospitalized for relapse event</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Proportion of patients hospitalized for relapse after treatment with oral vs intravenous steroids at week one</HEADING>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> found that 11 of 42 patients on oral MP and 10 of 38 patients on ivMP were hospitalized for their relapse at one week for a OR of 0.99 (95% CI 0.37 to 2.69) which is not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 02 - Prorportion of patients hospitalized for relapse after treatment with oral vs intravenous steroids at week four</HEADING>
<P>
<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> found that two of 42 patients on oral MP and one of 38 patients on ivMP were hospitalized for their relapse at week four for a OR of 1.85 (95% CI 0.16 to 21.26) which is not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 03 - Hospital length of stay</HEADING>
<P>The raw data were not available to analyze this as a continuous outcome.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 8: Pharmacological bioavailability of steroids</HEADING>
<P>
<LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK> measured the mean serum concentration and mean area under the curve of serum concentration of steroid measured at hours one, two, four, eight, 24 and 48 hours. Although the area under the curve was significantly greater in the IVMP group than the prednisone group at hours one, two,, and four hours. However, by eight hours, there was no statistically significant difference between groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 9: Immunological differences in titers of cytokines</HEADING>
<P>Pitzallis 1997 (<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>) examined the titers of TNF-alpha, LFA-1, LFA-3, ICAM-1, CD2, CD4, CD8, CD45Ra and CD45Ro at days one, four, 28 and 90 after steroid treatment. The actual data were not available for analysis, although all P values for group comparisons were not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 10: Gadolinium enhancing lesions on magnetic resonance imaging (MRI)</HEADING>
<P>Both <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> had MRI endpoints focused on gadolinium enhancing lesions and while both reported using an equivalence design, this was not apparent in the unpublished data and analyses supplied by <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>. In <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>, an equivalence-designed trial, the mean percentage change in gadolinium enhancing lesion number between groups was considered equivalent if the upper limit of the 95% CI of the oral group mean percentage lesion change was lower than 20% of the mean percentage lesion change of the IV group.</P>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Mean percentage reduction in gadolinium enhancing lesions on MRI between weeks zero and one</HEADING>
<P>The MD between IVMP and oral MP in <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> was -0.16 (95% CI of -0.41 to 0.09) while in <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> it was 0.14 (95% CI of -0.10 to 0.38) for a pooled MD of -0.01 (95% CI of -0.30 to 0.29), which is not statistically significant (and thus equivalent by <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>'s requirements).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 02 - Mean percentage reduction in gadolinium enhancing lesions on MRI between weeks zero and four</HEADING>
<P>The MD between IVMP and oral MP in <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> was -0.01 (95% CI of -0.35 to 0.33) while in <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> it was -0.02 (95% CI of -0.32 to 0.28) for a pooled MD of -0.02 (95% CI of -0.24 to 0.21), which is not statistically significant (and thus equivalent by <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>'s requirements).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 03 - Mean change in number of gadolinium enhancing lesions on MRI between weeks zero and one</HEADING>
<P>Both <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> measured the mean change in number of gadolinium enhancing lesions on MRI between weeks zero and one, which when pooled in 85 participants showed a MD of -0.14 (95% CI of -1.11 to 0.84) between oral MP and IVMP groups, which is not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 04 - Mean change in number of gadolinium enhancing lesions on MRI between weeks zero and four</HEADING>
<P>Both <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> measured the mean change in number of gadolinium enhancing lesions on MRI between weeks zero and four, which when pooled in 84 participants showed a MD of -0.18 (95% CI of 1.47 to 1.10), which is not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 05 - Proportion with gadolinium enhancing lesions on MRI at week one</HEADING>
<P>In <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>, 19 of 42 patients in the oral MP and 21 of 43 in the IVMP groups had gadolinium enhancing lesions on MRI at week one, for an OR of 0.86 (95% CI 0.37 to 2.03), which is not statistically significant.</P>
<P>Outcome 06 - Proportion with gadolinium enhancing lesions on MRI at week four</P>
<P>In <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>, 12 of 42 patients in the oral MP group and 11 of 42 patients in the IVMP group had gadolinium enhancing lesions on MRI at week four, for an OR of 1.13 (95% CI 0.43 to 2.99), which is not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison 11: T2 Lesions on MRI</HEADING>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 01 - Mean change in T2 lesion number at week one versus baseline</HEADING>
<P>In <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>, the MD between oral MP and iv MP groups is -0.09 (-0.33 to 0.15) - not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Outcome 02 - Mean change in T2 lesion number at weeks four versus week one</HEADING>
<P>In <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>, the MD between oral MP and ivMP groups is 0.14 (-0.24 to 0.52) - not statistically significant.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparisons 12-24: Adverse events</HEADING>
<P>See <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> "Adverse Event Outcomes" for detailed results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison: Cost (direct medical service cost and indirect costs of lost productivity)</HEADING>
<P>The eligible trials did not include this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Comparison: Quality of life</HEADING>
<P>The eligible trials did not include this outcome.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup Analysis</HEADING>
<P>Planned subgroup analyses according to age, baseline EDSS status, time to treatment and steroid type were not performed due to the paucity of available data. Assessment of publication bias by funnel plot analysis was not possible due to the absence of evidence of unpublished eligible trials. One observational trial comparing tolerability of oral versus IVMP was found (<LINK REF="STD-Le-Page-2007" TYPE="STUDY">Le Page 2007</LINK>), but was not eligible for inclusion in this review.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Despite good evidence of the effectiveness of high-dose oral steroid therapy for relapse events (<LINK REF="STD-Beck-1992" TYPE="STUDY">Beck 1992</LINK>; <LINK REF="STD-Alejandro-1994" TYPE="STUDY">Alejandro 1994</LINK>; <LINK REF="STD-Sellebjerg-1998" TYPE="STUDY">Sellebjerg 1998</LINK>), only five randomized trials with a total of 215 patients have directly compared the efficacy and safety of these therapies. Four of five trials used bioequivalent dosing , while one (<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>) used a low, but lengthy dosing regimen (three weeks) of oral MP versus the conventional 1000 mg of IVMP. With respect to the primary outcome of EDSS status at four weeks post steroid treatment, there was no statistically significant difference between the two routes of steroid administration. In addition, both based on the patient groups in <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>, Sharrack 2000 (<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>) provided evidence that relapse rates and disability status up to two years after treatment did not differ significantly between groups. <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> demonstrated that the degree of improvement in gadolinium enhancing lesion burden at four weeks was equivalent between oral MP and IVMP. While gadolinium enhancement within one week of treatment may be a very brief period of time over which to measure, the four-week assessment correlates better with both gadolinium persistence and clinical length of relapse (<LINK REF="REF-Swanton-2007" TYPE="REFERENCE">Swanton 2007</LINK>). <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> also showed that T2 lesion number does not differ in the month following relapse between treatment groups. A small pilot trial (<LINK REF="STD-Morrow-2004" TYPE="STUDY">Morrow 2004</LINK>) suggested steroid absorption does not differ significantly between bioequivalent doses of oral prednisone and IVMP in patients with relapsing MS. Only two trials (<LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK>; <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK>) clearly reported adverse event rates, most of which were evenly distributed between oral and intravenous groups. There was a trend towards more cases of dysgeusia (impaired sense of taste) and mood disturbance with oral steroid treatment.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Overall, all five trials had very thorough data reporting with virtually all patients accounted for. The results presented in these trials are the common outcomes of interest in the clinical care of patients with MS, and so these results would be quite generalizable and applicable with one caveat - not all patients have access to medical care or can be assessed within the first week of relapse. Furthermore, given that steroids hasten, but do not necessarily increase the degree of recovery from a relapse, those care providers and centers under resource constraints may elect not to see patients urgently with episodes considered "mild" in the early days of a relapse.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>While all trials demonstrated an absence of significant efficacy or safety differences between steroid regimens, there were methodological limitations which make inferences about the equivalence of oral and intravenous steroid therapy challenging at this stage. <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> and <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> both reported using a non-inferiority/equivalence methodology, but only <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> clearly used this design to estimate a target range of outcomes, sample size calculations, and analysis. However, such designs are more recent additions to clinical trial methodology. While <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> employed proper equivalence design techniques, the absence of blinding in patients or clinical evaluators for such outcomes as EDSS and adverse events could be a significant source of bias and error.</P>
<P>Additionally, the largest trial (<LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>), used an oral steroid dosing regimen that was not bioequivalent to the intravenous arm. Had bioequivalent dosing been used, the oral treatment arm could have potentially outperformed the intravenous arm, or conversely, been beset by a greater rate of adverse events. Furthermore, only <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK> and <LINK REF="STD-Ramo_x002d_Tello-2011" TYPE="STUDY">Ramo-Tello 2011</LINK> used reliable concealment of allocation, the absence of which can be as detrimental to the accuracy of trial results as the failure to randomize participants (<LINK REF="REF-Kunz-1998" TYPE="REFERENCE">Kunz 1998</LINK>). Finally, all trials, save <LINK REF="STD-Martinelli-2008" TYPE="STUDY">Martinelli 2008</LINK> allowed participants to enroll up to one month following a relapse, a time at which most patients with MS are entering the resolution phase of relapse activity. Enrolling participants within days and not weeks of a relapse event, could provide a more favorable window of opportunity to determine if the route of administration is a significant factor in the degree and timing of relapse recovery.</P>
<P>Many of the limitations of these trials are being addressed by the ongoing randomized double-blinded phase III Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA, <LINK REF="STD-OMEGA-2007" TYPE="STUDY">OMEGA 2007</LINK>) based out of the Mount Sinai School of Medicine and the Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses trial (<LINK REF="STD-COPOUSEP-2009" TYPE="STUDY">COPOUSEP 2009</LINK>) . The <LINK REF="STD-OMEGA-2007" TYPE="STUDY">OMEGA 2007</LINK> trial addresses the particular limitations of the delay to treatment seen in several existing trials (which may miss an hypothetical window in which oral and intravenous steroid therapy differ in efficacy), as well as the limited number of trials using bioequivalent dosing of oral and intravenous steroids when addressing clinical outcomes. Patients aged 18-50 with clinically definite relapsing forms of MS presenting with an objective relapse significant enough to merit steroid therapy will be considered for this trial. Patients will be randomly assigned to receive five consecutive days of either 1000 mg of IVMP (total 5000 mg) or 1400 mg of oral MP (bioequivalent to 1000 mg IVMP) within seven days of the onset of a relapse. A total of 120 participants will be recruited, although the statistical basis for this calculation was not available. The primary hypothesis is that oral and intravenous therapy will be equivalent with respect to EDSS status measured between days zero and 28 following treatment. Improvement in EDSS in this setting is defined as any magnitude of reduction in EDSS that meets statistical significance. Secondary endpoints of change in the MSFC, improvement in the subscale of the EDSS in which the relapse occurred, and the relapse rate up to one year following treatment with either steroid regimen. Enrolment for the OMEGA trial began in 2003 and recruitment is currently ongoing. The <LINK REF="STD-COPOUSEP-2009" TYPE="STUDY">COPOUSEP 2009</LINK> trial will enroll patients ages 18-55 after a clinical relapse (timing after onset not specified). Patients will be randomly assigned to receive consecutive three days of either 1000 mg of IVMP or 1000 mg or oral MP with the primary outcome of a minimum of a one-point reduction on the Kurtzke functional scale 28 days after treatment.  </P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-07-08 22:03:52 +0200" MODIFIED_BY="[Empty name]">
<P>While efforts were made to seek out unpublished reports of oral versus intravenous steroid use in MS relapses (e.g. conference abstracts), some unpublished material may have been missed. </P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-09-04 11:35:34 +0200" MODIFIED_BY="[Empty name]">
<P>While there have not been other meta-analyses of oral versus intravenous steroids in MS relapses published at this time, trials of oral steroids versus placebo have suggested the results are similar to trials of intravenous steroids. Additionally, trials looking at certain demyelinating events not formally diagnosed as MS (<LINK REF="STD-Beck-1992" TYPE="STUDY">Beck 1992</LINK>) suggest symptom resolution is similar between oral and intravenous steroids preparations.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Despite some limitations in trial number and number of patients, design heterogeneity and methodology, the analysis of the five eligible trials comparing intravenous and oral steroid therapy for MS relapses fails to demonstrate any significant differences in clinical (benefits and adverse events), radiological or pharmacological outcomes. Therefore, it would appear that based on the evidence, oral steroids for MS relapse events are a reasonable treatment alternative to intravenous steroids.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-06-18 12:04:20 +0200" MODIFIED_BY="[Empty name]">
<P>Larger scale trials such as <LINK REF="STD-OMEGA-2007" TYPE="STUDY">OMEGA 2007</LINK> and <LINK REF="STD-COPOUSEP-2009" TYPE="STUDY">COPOUSEP 2009</LINK>, should provide further data and sufficient power with which to make judgements about comparisons of the two regimens. Any future trials comparing oral and intravenous steroid treatment for relapses should employ a non-inferiority or equivalency design and the sample size determination that follows, as well as concealment of allocation, definitive methods of randomization, double blinding, masking of intervention and clear and meaningful endpoints.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-10-30 14:58:09 +0100" MODIFIED_BY="Liliana Coco">
<P>The authors would like to thank Dr. Luanne Metz, Dr. Richard Hughes, Dr. Vittorio Martinelli, Dr. Cristina Ramos and Dr. Ferran Torres or providing unpublished data for statistical analyses. The authors also thank Dr. Fred Lublin for providing additional information on the ongoing OMEGA trial and Dr. Armando Lorenzo for his assistance in translating. Finally, the authors express their gratitude for the assistance and guidance of Dr. Prakeshkumar Shah in the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>The authors have no conflict of interest to disclose.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-10-31 18:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Burton selected trials, assessed trial quality, determined inclusion and exclusion criteria, extracted and analyzed data and was the primary author of the review.</P>
<P>Dr. O'Connor independently reviewed abstracts for trial selection and quality, participated in data extraction and analysis and helped edit the review.</P>
<P>Dr. Hohol independently reviewed abstracts for trial selection and quality and will helped edit the review.</P>
<P>Dr. Beyene provided assistance and guidance in the statistical analysis of the data.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-10-25 03:14:31 +0200" MODIFIED_BY="[Empty name]"/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-10-26 11:22:06 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-10-26 11:06:50 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-10-23 01:46:41 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alam-1993" NAME="Alam 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alam SM, Kyriskides T, Lowden M, Newman PK</AU>
<TI>Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1993</YR>
<VL>56</VL>
<PG>1219-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Barnes-1997" MODIFIED="2012-10-15 17:47:59 +0200" MODIFIED_BY="[Empty name]" NAME="Barnes 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barnes D, Hughes RAC, Morris RW, Wade-Jones O, Brown P, Britton T, et al</AU>
<TI>Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>902-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pitzalis C, Sharrack B, Gray IA, Lee A, Hughes RAC</AU>
<TI>Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis</TI>
<SO>Journal of Neuroimmunology</SO>
<YR>1997</YR>
<VL>74</VL>
<NO>1-2</NO>
<PG>62-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-10-15 17:47:59 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sharrack B, Hughes RAC, Morris RW, Soudain S, Wade-Jones O, Barnes D, et al</AU>
<TI>The effect of oral and intravenous methylprednisolone treatment of subsequent relapse rate in multiple sclerosis</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>2000</YR>
<VL>173</VL>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Martinelli-2008" MODIFIED="2012-10-23 01:46:41 +0200" MODIFIED_BY="[Empty name]" NAME="Martinelli 2008" YEAR="2009">
<REFERENCE MODIFIED="2012-10-23 01:46:41 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;also presented at conference, but most data from direct correspondance with first author&lt;/p&gt;" NOTES_MODIFIED="2012-10-23 01:46:41 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Martinelli V, Pulizzi A, Annovazzi P, Rocca MA, Bucello S, Esposito F, et al</AU>
<TI>A single blind, randomised MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses A single blind, randomised MRI study comparing high-dose oral and intravenous methylprednisolone in treating MS relapses</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>73</VL>
<NO>22</NO>
<PG>1842-1848</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Morrow-2004" NAME="Morrow 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Morrow SA, Stoian CA, Dmitrovic J, Chan SC, Metz LM</AU>
<TI>The bioavailability of iv methylprednisolone and oral prednisone in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<PG>1079-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ramo_x002d_Tello-2011" MODIFIED="2012-10-15 17:56:19 +0200" MODIFIED_BY="[Empty name]" NAME="Ramo-Tello 2011" YEAR="2012">
<REFERENCE MODIFIED="2012-10-15 17:56:19 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ramo-Tello C, Grau-Lopez L, Giner P, Ramio-Torrenta L, Brieva L, Saiz A, et al</AU>
<TI>A multicentre, randomized clinical and MRI study of highdose oral versus intravenous methylprednisolone in MS</TI>
<SO>Multiple Sclerosis</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>10</NO>
<PG>Suppl 1 (S91-S92)</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-10-26 11:06:30 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Alejandro-1994" MODIFIED="2008-11-21 09:48:18 +0100" MODIFIED_BY="[Empty name]" NAME="Alejandro 1994" YEAR="1994">
<REFERENCE MODIFIED="2008-11-21 09:48:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alejandro PM, Castanon Gonzalez JA, Miranda Ruiz R, Edgar Echeverria R, Adriana Montano M</AU>
<TI>Comparative treatment of acute optic neuritis with "boluses" of intravenous methylprednisolone or oral prednisone</TI>
<SO>Gaceta Medica de Mexico</SO>
<YR>1994</YR>
<VL>130</VL>
<NO>4</NO>
<PG>227-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beck-1992" NAME="Beck 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, et al</AU>
<TI>A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group</TI>
<SO>New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>9</NO>
<PG>581-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Keyser-1999" MODIFIED="2008-11-21 09:48:50 +0100" MODIFIED_BY="[Empty name]" NAME="De Keyser 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-21 09:48:50 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>De Keyser J , Zwanikken CM, Zorgdrager A, Oenema D, Boon M</AU>
<TI>Treatment of acute relapses in multiple sclerosis at home with oral dexamethasone: a pilot study</TI>
<SO>Journal of Clinical Neuroscience</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>5</NO>
<PG>382-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Demirkiran-1995" NAME="Demirkiran 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Demirkiran M, Sarica Y, Karatas M, Bozdemir H</AU>
<TI>Efficacy of intravenous methylprednisolone and oral prednisone in multiple sclerosis</TI>
<SO>Annals of Medical Science</SO>
<YR>1995</YR>
<VL>4</VL>
<PG>91-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huen-1989" NAME="Huen 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Huen R, Emser W, Schimrigk S</AU>
<TI>Evoked potentials with intrathecal and systemic corticosteroid therapy in multiple sclerosis Evoked potentials with intrathecal and systemic corticosteroid therapy in multiple sclerosis</TI>
<SO>EEG-EMG Zeitschrift für Elektroenzephalographie, Elektromyographie und verwandte Gebiete</SO>
<YR>1989</YR>
<VL>20</VL>
<NO>2</NO>
<PG>88-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-La-Mantia-1994" NAME="La Mantia 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V</AU>
<TI>Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses</TI>
<SO>European Neurology</SO>
<YR>1994</YR>
<VL>34</VL>
<NO>4</NO>
<PG>199-203</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Le-Page-2007" NAME="Le Page 2007" YEAR="2007">
<REFERENCE NOTES="&lt;p&gt;abstract at 2007 ECTRIMS meeting&lt;/p&gt;" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Le Page E, Veillard D, Lavat C, Edan G</AU>
<TI>Intravenous versus oral tolerance of methylprednisolone high doses in multiple sclerosis: an observational study of 97 patients</TI>
<SO>Multiple Sclerosis</SO>
<YR>2007</YR>
<VL>13</VL>
<PG>S176</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Metz-1999" NAME="Metz 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Metz LM, Sabuda D, Hilsden R, Enns R, Meddings JB</AU>
<TI>Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<PG>2093</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Milanese-1989" MODIFIED="2008-11-21 09:49:38 +0100" MODIFIED_BY="[Empty name]" NAME="Milanese 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-11-21 09:49:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Milanese C, La Mantia L, Salmaggi A, Campi A, Eoli M, Scaioli V, et al</AU>
<TI>Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results</TI>
<SO>European Neurology</SO>
<YR>1989</YR>
<VL>29</VL>
<NO>1</NO>
<PG>10-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murray-1999" NAME="Murray 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Murray J</AU>
<TI>Oral methylprednisolone improved symptoms and disability resulting from multiple sclerosis attacks</TI>
<SO>Evidence-Based Medicine</SO>
<YR>1999</YR>
<VL>4</VL>
<NO>3</NO>
<PG>73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rohrbach-1988" MODIFIED="2012-10-15 18:00:11 +0200" MODIFIED_BY="[Empty name]" NAME="Rohrbach 1988" YEAR="1988">
<REFERENCE MODIFIED="2012-10-15 18:00:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;abstract only&lt;/p&gt;" NOTES_MODIFIED="2012-10-15 18:00:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Rohrbach E, Kappos L, Stadt D, Hennes A</AU>
<TI>Effects, side-effects and pharmacokinetics of intrathecal versus oral corticosteroids in spinal symptoms of multiple sclerosis: results of a double-blind controlled trial</TI>
<SO>Journal of Neurology</SO>
<YR>1988</YR>
<VL>235</VL>
<PG>S40-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00225511"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellebjerg-1998" MODIFIED="2008-11-21 09:50:02 +0100" MODIFIED_BY="[Empty name]" NAME="Sellebjerg 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-11-21 09:50:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J</AU>
<TI>Double blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<NO>2</NO>
<PG>529-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sellebjerg-1999" MODIFIED="2008-11-21 09:50:09 +0100" MODIFIED_BY="[Empty name]" NAME="Sellebjerg 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-11-21 09:50:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J</AU>
<TI>A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1479-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tankisi-1997" MODIFIED="2008-11-21 09:50:18 +0100" MODIFIED_BY="[Empty name]" NAME="Tankisi 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-11-21 09:50:18 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;abstract from Ectrims 1997, never published in full&lt;/p&gt;" NOTES_MODIFIED="2008-11-21 09:50:18 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Tankisi H, Oztekin N, Oztekin MF, Ozbakir S, Guven H, Guven B</AU>
<TI>Relative efficacy of intravenous methylprednisolone and oral prednisolone in the treatment of acute relapse in multiple sclerosis</TI>
<SO>Multiple Sclerosis</SO>
<YR>1997</YR>
<VL>Suppl 3</VL>
<PG>352</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="CN-00625757 (EMBASE)"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1989" MODIFIED="2008-11-21 09:50:35 +0100" MODIFIED_BY="[Empty name]" NAME="Thompson 1989" YEAR="1989">
<REFERENCE MODIFIED="2008-11-21 09:50:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AJ, Kennard C, Swash M, Summers B, Yuill GM, Shepherd DI, et al</AU>
<TI>Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS</TI>
<SO>Neurology</SO>
<YR>1989</YR>
<VL>39</VL>
<NO>7</NO>
<PG>969-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toczolowski-1995" MODIFIED="2012-10-26 11:06:16 +0200" MODIFIED_BY="[Empty name]" NAME="Toczolowski 1995" YEAR="1995">
<REFERENCE MODIFIED="2012-10-26 11:06:16 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Toczolowski J, Lewandowska-Furmanik M, Stelmasiak Z, Wozniak D, Chmiel M</AU>
<TI>Treatment of acute optic neuritis with large doses of corticosteroids</TI>
<SO>Klinika Oczna</SO>
<YR>1995</YR>
<VL>97</VL>
<PG>122-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tourtellotte-1965" MODIFIED="2012-10-26 11:06:30 +0200" MODIFIED_BY="[Empty name]" NAME="Tourtellotte 1965" YEAR="1965">
<REFERENCE MODIFIED="2012-10-26 11:06:30 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tourtellotte WW, Haerer AF</AU>
<TI>Use of an oral corticosteroid in the treatment of multiple sclerosis. A double -blind study</TI>
<SO>Archives of Neurology</SO>
<YR>1965</YR>
<VL>12</VL>
<PG>536-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2012-10-26 11:06:50 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-COPOUSEP-2009" MODIFIED="2012-05-31 22:34:46 +0200" MODIFIED_BY="[Empty name]" NAME="COPOUSEP 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2012-05-31 22:34:15 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-05-31 22:33:49 +0200" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00984984"/>
<IDENTIFIER MODIFIED="2012-05-31 22:34:15 +0200" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-OMEGA-2007" MODIFIED="2012-10-26 11:06:50 +0200" MODIFIED_BY="[Empty name]" NAME="OMEGA 2007" YEAR="2007">
<REFERENCE MODIFIED="2012-10-26 11:06:50 +0200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>Lublin F</AU>
<TI>Oral megadose corticosteroid therapy of acute exacerbations of multiple sclerosis (OMEGA) NCT00418145</TI>
<SO>www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-10-26 11:22:06 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-10-26 11:22:06 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Andersson-1998" NAME="Andersson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Andersson P-B, Goodkin DE</AU>
<TI>Glucocorticosteroid therapy for multiple sclerosis: a critical review</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1998</YR>
<VL>160</VL>
<PG>16-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brusaferri-2000" NAME="Brusaferri 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brusaferri F, Candelise L</AU>
<TI>Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials</TI>
<SO>Journal of Neurology</SO>
<YR>2000</YR>
<VL>247</VL>
<PG>435-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Confavreux-2006" NAME="Confavreux 2006" TYPE="JOURNAL_ARTICLE">
<AU>Confavreux C, Vukusic S</AU>
<TI>The natural history of multiple sclerosis</TI>
<SO>Revue du Practicien</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>12</NO>
<PG>1313-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-D_x0027_Amico-2007" MODIFIED="2012-10-26 11:20:23 +0200" MODIFIED_BY="Heather Maxwell" NAME="D'Amico 2007" TYPE="OTHER">
<AU>D'Amico R, Ebers G, Filippini G, Fredrikson S, Rice GPA, Simi S, et al</AU>
<TI>Cochrane Multiple Sclerosis Group</TI>
<SO>About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</SO>
<YR>2007</YR>
<NO>2</NO>
<PG>Art.No.:MS</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Filippini-2000" MODIFIED="2012-10-16 22:30:23 +0200" MODIFIED_BY="[Empty name]" NAME="Filippini 2000" TYPE="COCHRANE_REVIEW">
<AU>Filippini G, Brusaferri F, Sibley WA, Citterio A, Ciucci G, Midgard R, et al</AU>
<TI>Corticosteroids or ACTH for acute exacerbations in multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-10-16 22:30:23 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-10-16 22:30:23 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001331"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fisher-1999" NAME="Fisher 1999" TYPE="JOURNAL_ARTICLE">
<AU>Fisher JS, Rudick RA, Cutter GR, Reingold SC for the National MS Society Clinical Outcomes Assessment Task Force</AU>
<TI>The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment</TI>
<SO>Multiple Sclerosis</SO>
<YR>1999</YR>
<VL>5</VL>
<NO>4</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-10-26 11:20:03 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2011</YR>
<PB>John Wiley &amp; Sons</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jonsson-1951" NAME="Jonsson 1951" TYPE="JOURNAL_ARTICLE">
<AU>Jonsson B, Von Reis G, Sahlgren E</AU>
<TI>Experience of ACTH and cortisone treatment in some organic neurological cases</TI>
<SO>Acta Psychiatrica et Neurologica Scandinavica Supplementum</SO>
<YR>1951</YR>
<VL>74</VL>
<PG>60-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kunz-1998" MODIFIED="2008-11-21 11:21:31 +0100" MODIFIED_BY="[Empty name]" NAME="Kunz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kunz R, Oxman AD</AU>
<TI>The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials</TI>
<SO>BMJ (Clinical research ed.)</SO>
<YR>1998</YR>
<VL>317</VL>
<NO>7167</NO>
<PG>1185-90</PG>
<IDENTIFIERS MODIFIED="2008-11-21 11:21:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="9794851"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kurtzke-1983" NAME="Kurtzke 1983" TYPE="JOURNAL_ARTICLE">
<AU>Kurtzke JF</AU>
<TI>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1444-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2001" MODIFIED="2012-10-26 11:07:45 +0200" MODIFIED_BY="[Empty name]" NAME="McDonald 2001" TYPE="JOURNAL_ARTICLE">
<AU>McDonald IW, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, et al</AU>
<TI>Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis</TI>
<SO>Annals of Neurology</SO>
<YR>2001</YR>
<VL>50</VL>
<NO>1</NO>
<PG>121-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Necela-2004" MODIFIED="2012-10-26 11:07:59 +0200" MODIFIED_BY="[Empty name]" NAME="Necela 2004" TYPE="JOURNAL_ARTICLE">
<AU>Necela BM, Cidlowski JA</AU>
<TI>Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells</TI>
<SO>Proceedings of the American Thoracis Society</SO>
<YR>2004</YR>
<VL>1</VL>
<NO>3</NO>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noseworthy-2000" MODIFIED="2012-10-26 11:21:39 +0200" MODIFIED_BY="Heather Maxwell" NAME="Noseworthy 2000" TYPE="JOURNAL_ARTICLE">
<AU>Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG</AU>
<TI>Multiple sclerosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>13</NO>
<PG>938-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Brien-2003" NAME="O'Brien 2003" TYPE="JOURNAL_ARTICLE">
<AU>O'Brien JA, Ward AJ, Patrick AR, Cairo J</AU>
<TI>Cost of managing an episode of relapse in multiple sclerosis in the United States</TI>
<SO>BMC Health Services Research</SO>
<YR>2003</YR>
<VL>3</VL>
<PG>17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Polman-2005" MODIFIED="2012-10-26 11:21:58 +0200" MODIFIED_BY="[Empty name]" NAME="Polman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Polman CH, Reingold SC, Edan G, Filippi M, Hartung H-P, Kappos L et al</AU>
<TI>Diagnostic criteria for multiple sclerosis:2005 revisions to the &#8220;McDonald Criteria&#8221;</TI>
<SO>Annals of Neurology</SO>
<YR>2005</YR>
<VL>58</VL>
<NO>6</NO>
<PG>840-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poser-1983" MODIFIED="2012-10-26 11:22:06 +0200" MODIFIED_BY="[Empty name]" NAME="Poser 1983" TYPE="JOURNAL_ARTICLE">
<AU>Poser CM, Paty DW, Scheinberg L, McDonald I, Davis SA, Ebers GC, et al</AU>
<TI>New diagnostic criteria for multiple sclerosis: guidelines for research protocols</TI>
<SO>Annals of Neurology</SO>
<YR>1983</YR>
<VL>13</VL>
<NO>3</NO>
<PG>227-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rio-2006" NAME="Rio 2006" TYPE="JOURNAL_ARTICLE">
<AU>Río J, Nos C, Tintoré M, Téllez N, Galán I, Pelayo R, et al</AU>
<TI>Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients</TI>
<SO>Annals of Neurology</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>2</NO>
<PG>344-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robson-1998" NAME="Robson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Robson LS, Bain C, Beck S, Guthrie S, Coyte PC, O'Connor P</AU>
<TI>Cost analysis of methylprednisolone treatment of multiple sclerosis patients</TI>
<SO>Canadian Journal of Neurological Sciences</SO>
<YR>1998</YR>
<VL>25</VL>
<NO>3</NO>
<PG>222-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schumacher-1965" MODIFIED="2012-10-26 11:09:36 +0200" MODIFIED_BY="[Empty name]" NAME="Schumacher 1965" TYPE="JOURNAL_ARTICLE">
<AU>Schumacker GA, Beebe G, Kibler RF, Kurland LT, Kurtzke JF, McDowell F, et al</AU>
<TI>Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>1965</YR>
<VL>122</VL>
<PG>552&#8211;68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schweingruber-2011" MODIFIED="2012-10-26 11:21:04 +0200" MODIFIED_BY="[Empty name]" NAME="Schweingruber 2011" TYPE="JOURNAL_ARTICLE">
<AU>Schweingruber A, Reichardt SD, Reichardt HM</AU>
<TI>Mechanisms of glucocorticoids in control of neuroinflammation</TI>
<SO>Journal of Neuroendocrinology</SO>
<YR>2011</YR>
<VL>24</VL>
<PG>174-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sellebjerg-2000" MODIFIED="2012-10-26 11:21:22 +0200" MODIFIED_BY="[Empty name]" NAME="Sellebjerg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Sellebjerg F, Christiansen M, Jensen J, Frederiksen JL</AU>
<TI>Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis</TI>
<SO>European Journal of Neurology : the official journal of the European Federation of Neurological Societies</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>3</NO>
<PG>281-9</PG>
<IDENTIFIERS MODIFIED="2008-11-21 11:28:23 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="10886311"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Swanton-2007" MODIFIED="2012-10-26 11:11:07 +0200" MODIFIED_BY="[Empty name]" NAME="Swanton 2007" TYPE="JOURNAL_ARTICLE">
<AU>Swanton JK, Rovira A, Tintore M, Altmann DR, Barkhof F, Filippi M, et al</AU>
<TI>MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>8</NO>
<PG>677-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tremlett-1998" NAME="Tremlett 1998" TYPE="JOURNAL_ARTICLE">
<AU>Tremlett HL, Luscombe DK, Wiles CM</AU>
<TI>Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1998</YR>
<VL>65</VL>
<NO>3</NO>
<PG>362-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Troiano-1985" NAME="Troiano 1985" TYPE="JOURNAL_ARTICLE">
<AU>Troiano RA, Hafstein MP, Zito G, Ruderman MI, Dowling PC, Cook SD</AU>
<TI>The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques</TI>
<SO>Journal of the Neurological Sciences</SO>
<YR>1985</YR>
<VL>70</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-10-26 11:11:53 +0200" MODIFIED_BY="Heather Maxwell">
<REFERENCE ID="REF-Burton-2009" MODIFIED="2012-10-26 11:11:53 +0200" MODIFIED_BY="Heather Maxwell" NAME="Burton 2009" TYPE="COCHRANE_REVIEW">
<AU>Burton JM, O'Connor PW, Hohol M, Beyene J</AU>
<TI>Oral versus intravenous steroids for treatment of relapses in multiple sclerosis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-10-15 18:48:20 +0200" MODIFIED_BY="Heather Maxwell">
<IDENTIFIER MODIFIED="2012-10-15 18:48:20 +0200" MODIFIED_BY="Heather Maxwell" TYPE="DOI" VALUE="10.1002/14651858.CD006921.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Alam-1993">
<CHAR_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>1.Concealment of allocation and randomization methods - can not tell<BR/>2.Blinding of assessors and participants and tests of blinding - yes blinding of participants, but can not tell if tests of blinding done<BR/>3.Masking of intervention - yes<BR/>4.Rationale for sample size - yes<BR/>5.Use of non-inferiority design and analysis methods - no<BR/>6Use of ITT analysis possible with published data - yes<BR/>7. Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>38 adults with clinically definite MS presenting with a relapse &lt;=4 weeks in duration and severe enough to merit steroid treatment were randomized to oral MP (18 patients) or IVMP (20 patients). Three patients withdrew from the IVMP group. Mean age was 41.5 years (19-72), mean disease duration was 5.4 years (0.1-27) and the sex ratio was 26 women to 9 men.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>IVMP group: 500 mg/d of intravenous MP was given for three days in 100 mL of saline solution. Oral MP group: 500mg/d of oral MP for three days as five 100 mg tablets. Sham tablets were given to the IVMP group while sham intravenous saline solution was given to the oral MP group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 19:01:17 +0200" MODIFIED_BY="Heather Maxwell">
<P>1. Mean EDSS at day 28; 2. Mean EDSS at day 7; 3. Adverse event rates</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Rates of specific adverse events were not reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Barnes-1997">
<CHAR_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>1.Concealment of allocation and randomization methods - yes<BR/>2.Blinding of assessors and participants and tests of blinding - yes to both<BR/>3.Masking of intervention - yes<BR/>4.Rationale for sample size - yes<BR/>5.Use of non-inferiority design and analysis methods - no<BR/>6.Use of ITT analysis possible with published data - yes<BR/>7. Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>80 adults with clinically definite MS presenting with relapses &lt;= 4 weeks severe enough to merit steroid treatment were randomized to oral MP group (42 patients) or IVMP group (38 patients). Mean age in oral MP group 38.0 years (9.6 SD) and in IVMP group 37.0 years (11.1 SD). The sex ratio was 51 women to 29 men.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>IVMP group: 1 g/d of intravenous MP was given for three days in 100 mL of a 5% dextrose solution.<BR/>Oral MP group: 48 mg/d x 7d, then 24 mg/d x 7d, then 12 mg/d x 7d. Sham tablets were given to the IVMP group while sham intravenous solution was given to the oral MP group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>1.Primary endpoint reported to be proportion of patients with improvement of EDSS &gt;= 1 point at four weeks, but result not reported;<BR/>2.Median EDSS at 0-1 weeks, 0-4 weeks, 0-12 weeks, 0-24 weeks and overall area under the curve;<BR/>3.Median ambulation index at 0-1 weeks, 0-4 weeks, 0-12 weeks, 0-24 weeks and overall area under the curve;<BR/>4.Median arm index at 0-1 weeks, 0-4 weeks, 0-12 weeks, 0-24 weeks and overall area under the curve;<BR/>5.Proportion discharged from hospital at week 1 and week 4;<BR/>6.Mean hospital length of stay;<BR/>7.Proportion with improvement in pyramidal FSS subscale;<BR/>8.Adverse event rates</P>
<P>Outcomes from Pitzallis 1997:<BR/>1.TNF alpha at day 1, 4, 28 and 90;<BR/>2.LFA-1 at day 1, 4, 28 and 90;<BR/>3.LFA-3 at day 1, 4, 28 and 90;<BR/>4.ICAM-1 at day 1, 4, 28 and 90;<BR/>5.CD2 at day 1, 4, 28 and 90;<BR/>6.CD4 at day 1, 4, 28 and 90;<BR/>7.CD8 at day 1, 4, 28 and 90;<BR/>8.CD45Ra at day 1, 4, 28 and 90;<BR/>9.CD45Ro at day 1, 4, 28 and 90</P>
<P>Outcomes from Sharrack 2000, based on participants from <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>:<BR/>1.Proportion of patients with relapses over 2 years following treatment;<BR/>2.Number of relapses over 2 years;<BR/>3.Mean relapse rate in first 6 months after therapy;<BR/>3.Mean relapse rate in first year following therapy;<BR/>4.Mean relapse rate in second year following therapy;<BR/>5.Annualized relapse rate over 2 years following therapy;<BR/>6. Number of verified relapses;<BR/>7.Number of treated relapses;<BR/>8.Mean days until first relapse after treatment;<BR/>9.Mean EDSS of first relapse after treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-15 19:07:34 +0200" MODIFIED_BY="Heather Maxwell">
<P>Articles Pitzallis 1997 and Sharrack 2000 are based on the patients from <LINK REF="STD-Barnes-1997" TYPE="STUDY">Barnes 1997</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinelli-2008">
<CHAR_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>1.Concealment of allocation and randomization methods - randomization methods - yes, concealment of allocation - no<BR/>2.Blinding of assessors and participants and tests of blinding - no (only radiologists blinded)<BR/>3.Masking of intervention - no<BR/>4.Rationale for sample size - yes<BR/>5.Use of non-inferiority design and analysis methods - yes<BR/>6.Use of ITT analysis possible with published data - yes<BR/>7. Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>40 adults (&lt; age 55 years) with clinically definite MS presenting with relapses &lt;= 2 weeks that were moderate to severe in intensity with =&gt; 1gadolinium enhancing lesion on MRI done at time of relapse were randomized to oral MP group (20 patients) or IVMP group (20 patients). Mean age in oral MP group 36.0 years (8 SD) and in IVMP group 31.0 years (7 SD). The mean EDSS is the oral MP group was 2.3 (1.3 SD) and in the IVMP group it was 1.8 (1.1). Mean disease duration in the oral MP group was 10 years (6 SD) while in the IVMP group it was 7 years (6 SD). The sex ratio was 14 women to 6 men in each group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>IVMP group: 1gram/d of intravenous MP given for 5 consecutive days<BR/>Oral MP group: 500 mg of oral MP given BID for 5 consecutive days.<BR/>Both groups received sucralfate 2 g for 3 days for gastrointestinal protection</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-15 19:10:11 +0200" MODIFIED_BY="Heather Maxwell">
<P>1.The range over which reduction the number of gadolinium enhancing lesions on MRI after 1 week from the beginning steroid treatment falls<BR/>(Oral MP equivalent to IVMP group if the upper limit of the 95% CI of the oral MP group mean percentage lesion change was lower than 20% of the average percentage lesion change of the IVMP group<BR/>2.Number of gadolinium enhancing lesions on MRI 4 weeks after steroid treatment<BR/>3. Change in EDSS score 1 week after steroid treatment<BR/>4.Change in EDSS score 4 weeks after steroid treatment<BR/>5.Safety profile</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Morrow-2004">
<CHAR_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>1.Concealment of allocation and randomization methods - can not tell<BR/>2.Blinding of assessors and participants and tests of blinding - no<BR/>3.Masking of intervention - no<BR/>4.Rationale for sample size - can not tell<BR/>5.Use of non-inferiority design and analysis methods - no<BR/>6.Use of ITT analysis possible with published data - no<BR/>7. Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew - no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>16 adults (&gt;18 years of age) with multiple sclerosis presenting with relapse events severe enough to merit steroid therapy were randomized in equal numbers to one of two groups<BR/>Mean age 39 (24-61)<BR/>Mean EDSS 4.0 (2-6.5)<BR/>Mean disease duration 5.7 years (0.6-38 years)<BR/>Women: Men 13:4</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>16 adults with MS presenting with relapses severe enough to merit steroid treatment were randomized in equal number to oral MP or IVMP. The mean age was 39 years (24-61), mean EDSS was 4.0 (2-6.5) and mean disease duration was 5.7 years (0.6-38). The sex ratio was 13 women to 4 men.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>1.Mean absorption of steroid absorption by liquid chromatography/mass spectrometry at 1, 2, 4, 8, 24 and 48 hours following treatment;<BR/>2.Mean area under the curve for absorption by liquid chromatography/mass spectrometry at 1, 2, 4, 8, 24 and 48 hours following treatment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>Raw data made available reported 17, not 16 patients. Unclear which patient deleted (hence 17 patients when Female: Male numbers reported). As well, only 15 patients used in this review as 2 patients were treated &gt; 30 days after relapse event.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<CHAR_METHODS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>1.Concealment of allocation and randomization methods - yes<BR/>2.Blinding of assessors and participants and tests of blinding - yes<BR/>3.Masking of intervention - yes<BR/>4.Rationale for sample size - yes<BR/>5.Use of non-inferiority design and analysis methods - unclear<BR/>6.Use of ITT analysis possible with published data - N/A (unpublished data)<BR/>7. Complete follow-up with documentation of the number of patients lost to follow-up and those who withdrew - yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-05-21 18:25:40 +0200" MODIFIED_BY="[Empty name]">
<P>Forty-eight adults with MS and a mean age of 38 years and a sex ratio of 40 women to 8 men presenting with an MS relapse deemed to require steroid therapy </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>1.IV Group: 1000 mg IVMP with sham oral agent for 3 consecutive days</P>
<P>2.Oral Group: 250 mg of oral MP for with sham iv agent for 3 consecutive days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>1.Mean EDSS in oral MP vs IVMP groups at day 7, 28 and month 3</P>
<P>2.Number and volume of new and persistent gadolinium enhancing lesions on MRI brain at day 7, 28 and month 3</P>
<P>3.Number and volume of new and persistent T2 lesions on MRI brain at day 7, 28 and month 3</P>
<P>4.Adverse event rates</P>
<P>5.MFIS</P>
<P>6.MUSIQoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-05-21 18:06:03 +0200" MODIFIED_BY="[Empty name]">
<P>Unpublished data, raw data supplied for all outcomes but unclear if all will be reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BID: twice daily<BR/>d: day(s)<BR/>EDSS: Expanded Disability Status Scale<BR/>FSS: Fatigue Severity Scale <BR/>ITT: intention-to-treat<BR/>IVMP: intravenous methylprednisolone<BR/>MFIS: Modified Fatigue Impact Scale <BR/>MP: methylprednisolone<BR/>MRI: magnetic resonance imaging<BR/>MS: multiple sclerosis<BR/>MUSIQoL: Multiple Sclerosis International Quality of Life<BR/>oral MP: oral methylprednisolone<BR/>SD: standard deviation<BR/>vs: versus<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Alejandro-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>This randomized controlled trial of oral versus intravenous methylprednisolone was performed in patients with optic neuritis, and the majority of patients did not have MS. Too few participants with MS made analyzing this subgroup of little value.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beck-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>This randomized blinded and controlled trial was performed in patients with optic neuritis only, not those with MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-De-Keyser-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This was a non-randomized trial of MS relapse treatment with oral dexamethasone only.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Demirkiran-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial was not a comparison of intravenous versus oral steroids, but rather a study of intravenous + oral steroids versus oral steroids alone. Additionally, not all patients had definite MS, and no breakdown of results based on this parameter.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Huen-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>This trial compared intravenous to intrathecal steroid administration in patients with MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-La-Mantia-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>This double-blind trial compared intravenous dexamethasone to intravenous methylprednisolone in MS relapses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Le-Page-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>This trial was an observational, non-randomized study of consecutive patients with MS treated with either high-dose oral or intravenous MP. Consecutive patients received either 3-5 days of IVMP or 3-5 days starting on day 1 with IVMP, followed by 2 days with oral MP. Roughly 80% of patients were treated for relapses, the remainder for a test of steroid responsiveness.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell" STUDY_ID="STD-Metz-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="Heather Maxwell">
<P>This trial compared gastric and small bowel permeability between participants on oral prednisone at 1250mg versus 1000 mg of IVMP. Patients chose their treatment, so this was not a randomized trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Milanese-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial compared methylprednisolone to dexamethasone to ACTH in acute MS relapses. No drug was administered orally.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murray-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>This trial did not have an active comparator for oral methylprednisolone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rohrbach-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>This double-blinded randomized controlled trial compared oral and intrathecal corticosteroids to treat myelopathic symptoms of MS, not overt relapses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sellebjerg-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>This randomized controlled trial of treatment for MS relapses used oral methylprednisolone against placebo, not an intravenous steroid preparation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-21 15:08:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sellebjerg-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-21 15:08:57 +0200" MODIFIED_BY="[Empty name]">
<P>This randomized controlled trial compared oral methylprednisolone against placebo in patients with optic neuritis, not necessarily MS.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-09-04 11:36:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tankisi-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-09-04 11:36:44 +0200" MODIFIED_BY="[Empty name]">
<P>Patients encountering "acute" relapses were treated with either 1g daily of IVMP followed by oral prednisolone taper or prednisolone taper alone. The trial was only published in abstract form, is not clearly an RCT, and does not compare intravenous to oral steroids, but intravenous plus oral steroids versus oral steroids alone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>This double-blind randomized trial compared intravenous methylprednisolone to intramuscular ACTH.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-21 15:07:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toczolowski-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-21 15:07:56 +0200" MODIFIED_BY="[Empty name]">
<P>Upon translation from Polish to English, it was evident that this was not a randomized controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tourtellotte-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>This double-blind randomized trial compared oral methylprednisolone to oral cyanocobalamin.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>ACTH: adrenocorticotropic hormone<BR/>IVMP: intravenous methylprednisolone<BR/>MP: methylprednisolone<BR/>MS: multiple sclerosis<BR/>RCT: randomized controlled trial<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2012-06-21 15:08:08 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-COPOUSEP-2009">
<CHAR_STUDY_NAME MODIFIED="2012-03-28 00:05:03 +0200" MODIFIED_BY="[Empty name]">
<P>Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses (COPOUSEP)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-03-28 00:09:04 +0200" MODIFIED_BY="[Empty name]">
<P>Double-blinded randomized trial of oral versus iv methylprednisolone.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-21 15:08:08 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with clinically definite MS ages 18-55 and EDSS 0-5.0. All must present with an acute symptomatic exacerbation of MS present for great than 24 hours within 15 days of the event.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-28 00:08:01 +0200" MODIFIED_BY="[Empty name]">
<P>1000 mg oral methylprednisolone versus 1000 mg of iv methylprednisolone for three days for relapses within 15 days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-28 00:08:32 +0200" MODIFIED_BY="[Empty name]">
<P>A minimum of a one point reduction in EDSS at day 28</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2012-03-28 00:08:43 +0200" MODIFIED_BY="[Empty name]">
<P>March 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2012-03-28 00:09:21 +0200" MODIFIED_BY="[Empty name]">
<P>Emmanuelle LE PAGE, MD, 33-2-9928-5296, <A HREF="mailto:emmanuelle.lepage%40chu-rennes.fr?subject=NCT00984984, 2007-000590-37, Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses">emmanuelle.lepage@chu-rennes.fr</A>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-03-28 00:09:40 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator contacted, no data available to report as of January 2012</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-OMEGA-2007">
<CHAR_STUDY_NAME>
<P>Oral Megadose Corticosteroid Therapy of Acute Exacerbations of Multiple Sclerosis (OMEGA)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2012-06-21 15:08:12 +0200" MODIFIED_BY="[Empty name]">
<P>Bioequivalent oral dosing methylprednisolone plus intravenous placebo versus IVMP plus oral placebo for objective acute relapses seen within seven days of event. Patients followed for one year.<BR/>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>Patients with clinically definite MS (by Poser or McDonald criteria) between the ages of 18 and 50 years with an EDSS of 2-6.5 at entry. All must present with an acute symptomatic exacerbation of MS present for great than 24 hours and less than or equal to 7 days at entry with new or worsening symptoms (excluding purely sensory deficits if not optic neuritis). Signs must be referable to the symptoms and not in the context of fever or active infection.<BR/>
<BR/>Participants may continue on their current immunomodulating therapy (such as interferons or glatiramer acetate) throughout the course of the study. Women who become pregnant after the 5-day treatment of steroids will have their immunomodulatory treatment discontinued.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-10-13 18:30:13 +0200" MODIFIED_BY="[Empty name]">
<P>Equivalent oral methylprednisolone (1400 mg/day x 5 days plus intravenous placebo) versus IVMP (1000mg/d x 5 days plus oral placebo) in patients seen within seven days of an acute exacerbation of MS.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<P>The primary outcome measures include EDSS and mean recovery from day 0 to day 28 (time frame: Day 28 and Day 90, Designated as safety issue: Yes)<BR/>
<BR/>Secondary outcome measures: clinical parameters of the MSFC between oral and IV steroid therapy in participants with relapsing forms of MS (time frame: Day 28 and day 90). frequency of relapse over time (up to one year) when participants with relapsing forms of MS are administered one course of oral methylprednisolone compared with IV administration (time frame: Day 28 and day 90 and day 365),improvement using Targeted Neurological Deficits (TND, time frame: Day 28 and day 90).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-10-13 18:35:40 +0200" MODIFIED_BY="[Empty name]">
<P>September 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-10-13 18:36:27 +0200" MODIFIED_BY="[Empty name]">
<P>Michele Weber (212)-241-4264, Principle Investigator is Dr. Fred Lublin.       </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2012-03-28 00:09:58 +0200" MODIFIED_BY="[Empty name]">
<P>Principal investigator contacted, no data available to report as of January 2012</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Study is currently enrolling final data collection by December 2009.</P>
<P>EDSS: Expanded Disability Status Scale<BR/>IVMP: intravenous methylprednisolone<BR/>MS: multiple sclerosis<BR/>MSFC: Multiple Sclerosis Functional Composite<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-05-21 18:27:12 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:14:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>Randomization methods unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:26:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Randomization methods adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:22:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Randomization methods adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:22:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Cannot determine what randomization techniques used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:27:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Randomization methods adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-05-21 18:27:20 +0200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:14:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>Allocation concealment methods unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:18:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Proper use and documentation of concealment of allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:22:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Concealment of allocation not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:27:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Unclear if concealment of allocation used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-05-21 18:27:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Allocation concealment methods adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-05-21 18:14:53 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-21 18:18:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>Blinding methods sufficient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-21 18:18:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Blinding methods sufficient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-05-31 22:28:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Only radiologists blinded, not clear clinical evaluators or patients blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-09-04 11:36:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Performed only in laboratory evaluators (but outcomes pharmacological)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Blinding sufficient</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-21 15:06:46 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-21 18:15:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>Tests of blinding not documented so unclear if performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-21 18:19:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Tests of blinding performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-21 18:21:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Unclear if tests of blinding performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-21 15:06:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Not performed (but outcomes pharmacological)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-05-21 18:28:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Tests of blinding performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-10-25 03:31:20 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-10-25 03:31:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>Patients lost to follow-up/withdrawals documented although exact reasons not clear, use of ITT with published data possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-21 18:19:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Patients lost to follow-up/withdrawals documented, use of ITT with published data possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-21 18:22:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Patients lost to follow-up/withdrawals documented, use of ITT with published data possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-21 18:32:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Patients lost to follow-up/withdrawals not clearly documented, additional data supplied by author</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-05-21 18:28:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Unpublished data only, all data available was supplied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-10-26 04:06:07 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-26 04:05:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>No clear evidence that data intentionally left undocumented although some enpoint data not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-26 04:04:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>No clear evidence that data intentionally left undocumented although some endpoints not clearly reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-26 04:06:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>No evidence endpoint data undocumented</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-26 03:38:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>Some patient data missing in final report but author supplied additional raw data upon request</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-23 01:19:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Unpublished data at present, but all requested data supplied</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2012-10-26 04:06:35 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Rationale for sample size</NAME>
<DESCRIPTION>
<P>Was the sample size for the trial calculated to demonstrate adequate power and error estimation?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-25 04:14:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>A sample size calculation was provided but a power value was not</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>Sample size calculations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>Sample size calculations were provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>The authors report that their sample size does not provide adequate power</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-26 04:06:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>Sample size calculations were provided and adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2012-09-04 11:44:48 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Use of non-inferiority design and methods</NAME>
<DESCRIPTION>
<P>To determine if oral and iv treatments are equivalent, this methodology is most appropraite</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:14 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Alam-1993">
<DESCRIPTION>
<P>This design was not employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:27 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Barnes-1997">
<DESCRIPTION>
<P>This design was not employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinelli-2008">
<DESCRIPTION>
<P>A non-inferiority design was employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:42:52 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morrow-2004">
<DESCRIPTION>
<P>This design was not employed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 01:43:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ramo_x002d_Tello-2011">
<DESCRIPTION>
<P>The authors state a non-inferiority design was employed, but the results are not presented as such (i.e. they are presented as a comparison of mean values)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2012-10-26 10:54:07 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Results of Search Strategies for Eligible Trials</TITLE>
<TABLE COLS="5" ROWS="4">
<TR>
<TH>
<P>Publication</P>
</TH>
<TH>
<P>MEDLINE (1950-Jul 08)</P>
</TH>
<TH>
<P>EMBASE (1980-Jul 08)</P>
</TH>
<TH>
<P>CENTRAL (Jul 08)</P>
</TH>
<TH>
<P>Abstracts</P>
</TH>
</TR>
<TR>
<TD>
<P>Citations Found</P>
</TD>
<TD>
<P>243</P>
</TD>
<TD>
<P>305</P>
</TD>
<TD>
<P>82</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>Abstracts Considered for Eligibility</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>16</P>
</TD>
<TD>
<P>4</P>
</TD>
</TR>
<TR>
<TD>
<P>Included Studies</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>2</P>
</TD>
<TD>
<P>3</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2012-10-16 10:18:28 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2012-07-13 21:01:23 +0200" MODIFIED_BY="[Empty name]">Adverse Event Outcomes</TITLE>
<TABLE COLS="5" ROWS="14">
<TR>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Patients with Outcome</B>
</P>
<P>
<B>Oral Group</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Patietns with Outcome</B>
</P>
<P>
<B>IV Group</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Odds Ratio in Favour of Outcome in Oral Group</B>
</P>
<P>
<B>(95% CI)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>
<B>Statistically</B>
</P>
<P>
<B>Significant?</B>
</P>
<P>
<B>(Y/N)</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>hypertension</P>
</TD>
<TD ALIGN="CENTER">
<P>2/20</P>
</TD>
<TD ALIGN="CENTER">
<P>1/20</P>
</TD>
<TD ALIGN="CENTER">
<P>2.11 (0.18, 25.35)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>rash</P>
</TD>
<TD ALIGN="CENTER">
<P>7/45</P>
</TD>
<TD ALIGN="CENTER">
<P>9/44</P>
</TD>
<TD ALIGN="CENTER">
<P>0.72 (0.23, 26)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>hypertrichosis</P>
</TD>
<TD ALIGN="CENTER">
<P>1/20</P>
</TD>
<TD ALIGN="CENTER">
<P>2/20</P>
</TD>
<TD ALIGN="CENTER">
<P>0.47 (0.04, 5.69)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>anxiety</P>
</TD>
<TD ALIGN="CENTER">
<P>14/45</P>
</TD>
<TD ALIGN="CENTER">
<P>14/44</P>
</TD>
<TD ALIGN="CENTER">
<P>0.95 (0.37, 2.44)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>insomnia</P>
</TD>
<TD ALIGN="CENTER">
<P>28/45</P>
</TD>
<TD ALIGN="CENTER">
<P>20/44</P>
</TD>
<TD ALIGN="CENTER">
<P>2.63 (0.63, 11.01)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>dysgeusia</P>
</TD>
<TD ALIGN="CENTER">
<P>26/45</P>
</TD>
<TD ALIGN="CENTER">
<P>15/44</P>
</TD>
<TD ALIGN="CENTER">
<P>4.30 (1.36, 13.63)</P>
</TD>
<TD ALIGN="CENTER">
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>hiccups</P>
</TD>
<TD ALIGN="CENTER">
<P>1/20</P>
</TD>
<TD ALIGN="CENTER">
<P>0/20</P>
</TD>
<TD ALIGN="CENTER">
<P>3.15 (0.12, 82.16)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>hyperglycemia</P>
</TD>
<TD ALIGN="CENTER">
<P>0/20</P>
</TD>
<TD ALIGN="CENTER">
<P>1/20</P>
</TD>
<TD ALIGN="CENTER">
<P>0.32 (0.01, 8.26)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>headache</P>
</TD>
<TD ALIGN="CENTER">
<P>18/24</P>
</TD>
<TD ALIGN="CENTER">
<P>13/24</P>
</TD>
<TD ALIGN="CENTER">
<P>2.54 (0.75, 8.63)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>mood disturbance</P>
</TD>
<TD ALIGN="CENTER">
<P>13/24</P>
</TD>
<TD ALIGN="CENTER">
<P>7/24</P>
</TD>
<TD ALIGN="CENTER">
<P>2.87 (0.87, 9.45)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>hot flashes</P>
</TD>
<TD ALIGN="CENTER">
<P>14/24</P>
</TD>
<TD ALIGN="CENTER">
<P>11/24</P>
</TD>
<TD ALIGN="CENTER">
<P>1.65 (0.53, 5.18)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>edema</P>
</TD>
<TD ALIGN="CENTER">
<P>5/24</P>
</TD>
<TD ALIGN="CENTER">
<P>9/24</P>
</TD>
<TD ALIGN="CENTER">
<P>0.44 (0.12, 1.59)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>pirosis</P>
</TD>
<TD ALIGN="CENTER">
<P>10/24</P>
</TD>
<TD ALIGN="CENTER">
<P>10/24</P>
</TD>
<TD ALIGN="CENTER">
<P>0.98 90.36, 2.67)</P>
</TD>
<TD ALIGN="CENTER">
<P>N</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-09-12 10:21:29 +0200" MODIFIED_BY="Liliana Coco">
<COMPARISON ID="CMP-001" MODIFIED="2012-09-12 10:20:00 +0200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Improvement in EDSS after treatment with oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="5.802873582887677" CI_END="0.2810034054174002" CI_START="-0.3840264550562281" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.05151152481941393" ESTIMABLE="YES" I2="65.53431724072227" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2012-02-18 21:35:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05494429962283287" P_Q="1.0" P_Z="0.7614115691799332" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.056557310248550624" TOTALS="YES" TOTAL_1="86" TOTAL_2="82" UNITS="" WEIGHT="100.00000000000001" Z="0.30362766977978733">
<NAME>Mean decrease in EDSS after steroid treatment at week 1</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.4287417161626934" CI_START="-0.22874171616269345" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="0.4" ORDER="41" SD_1="0.8" SD_2="0.7" SE="0.16772844743871118" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="33.985468082829996"/>
<CONT_DATA CI_END="-0.054592851350137694" CI_START="-0.7054071486498623" EFFECT_SIZE="-0.38" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="0.98" ORDER="42" SD_1="0.53" SD_2="0.52" SE="0.16602710622064099" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="34.214872612746525"/>
<CONT_DATA CI_END="0.5011558293050039" CI_START="-0.22115582930500388" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="0.64" MEAN_2="0.5" MODIFIED="2012-02-18 21:35:24 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="0.7" SD_2="0.57" SE="0.18426656415819626" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="24" TOTAL_2="24" WEIGHT="31.79965930442349"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.217428174218966" CI_END="0.26181872058493355" CI_START="-0.7110261987576783" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.22460373908637238" ESTIMABLE="YES" I2="37.838550180362546" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2012-09-12 10:20:00 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.20014496053358521" P_Q="1.0" P_Z="0.36546222433264475" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.06809537415114456" TOTALS="YES" TOTAL_1="84" TOTAL_2="81" UNITS="" WEIGHT="99.99999999999999" Z="0.905005989443397">
<NAME>Mean decrease in EDSS after steroid treatment at week 4</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6040112059263013" CI_START="-0.40401120592630135" EFFECT_SIZE="0.09999999999999998" ESTIMABLE="YES" MEAN_1="0.9" MEAN_2="0.8" ORDER="43" SD_1="1.2" SD_2="1.1" SE="0.2571532997044218" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="45.88846058848708"/>
<CONT_DATA CI_END="-0.08070969134850409" CI_START="-0.9192903086514959" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.95" MEAN_2="1.45" ORDER="44" SD_1="0.63" SD_2="0.72" SE="0.21392755783208484" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="54.09516506583664"/>
<CONT_DATA CI_END="37.90951504121589" CI_START="-38.10951504121589" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.09" MEAN_2="1.19" MODIFIED="2012-02-18 21:34:20 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="0.98" SD_2="93.0" SE="19.392966065208388" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" WEIGHT="0.016374345676272033"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-02-18 21:38:40 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Proportion of patients with improvement on EDSS after treatment with oral vs. intravenous steroids</NAME>
<DICH_OUTCOME CHI2="1.4387429844426047" CI_END="1.264188651411303" CI_START="0.28109116532070993" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5961143021354377" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.10181188735895587" LOG_CI_START="-0.5511528040288469" LOG_EFFECT_SIZE="-0.22467045833494553" METHOD="MH" MODIFIED="2012-02-18 21:38:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6964788345631576" P_Q="1.0" P_Z="0.17741438328125206" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="99" TOTAL_2="101" WEIGHT="100.0" Z="1.3487590141840422">
<NAME>Proportion of patients with improvement on EDSS after steroid treatment at 4 weeks</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3181449271224595" CI_START="0.10784485347528634" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.3651405839494188" LOG_CI_START="-0.9672005752773812" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="45" O_E="0.0" SE="0.7826237921249264" STUDY_ID="STD-Alam-1993" TOTAL_1="15" TOTAL_2="20" VAR="0.6125" WEIGHT="24.018645178080703"/>
<DICH_DATA CI_END="1.8934540498345767" CI_START="0.22923632234143493" EFFECT_SIZE="0.6588235294117647" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.2772547701669439" LOG_CI_START="-0.6397165675831284" LOG_EFFECT_SIZE="-0.18123089870809234" ORDER="46" O_E="0.0" SE="0.5386335028757198" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" VAR="0.29012605042016804" WEIGHT="50.706994943297836"/>
<DICH_DATA CI_END="2.526751655253808" CI_START="0.005885857404936664" EFFECT_SIZE="0.12195121951219512" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.4025625588755845" LOG_CI_START="-2.230190263643018" LOG_EFFECT_SIZE="-0.9138138523837167" ORDER="47" O_E="0.0" SE="1.5464920402840814" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="2.391637630662021" WEIGHT="6.1511911265178645"/>
<DICH_DATA CI_END="5.300410280532595" CI_START="0.17026983803776696" EFFECT_SIZE="0.95" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="20" LOG_CI_END="0.7243094876526779" LOG_CI_START="-0.7688622770749824" LOG_EFFECT_SIZE="-0.022276394711152253" MODIFIED="2012-02-18 21:38:40 +0100" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.8770964859204687" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" VAR="0.769298245614035" WEIGHT="19.1231687521036"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2008-10-13 23:35:15 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Change in Ambulation Index after treatment with oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.39492911357607846" CI_START="-0.39492911357607846" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" MODIFIED="2008-10-13 23:35:15 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.0" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.0">
<NAME>Change in Ambulation Index at week 1 after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.39492911357607846" CI_START="-0.39492911357607846" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.4" ORDER="48" SD_1="0.9" SD_2="0.9" SE="0.20149814827784027" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.9056322848449505" CI_START="-0.10563228484495046" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.12102025568052965" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.5505054113710854">
<NAME>Change in Ambulation Index at week 4 after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.9056322848449505" CI_START="-0.10563228484495046" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.4" ORDER="49" SD_1="1.3" SD_2="1.0" SE="0.25798039598345346" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-09-12 10:19:35 +0200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Longterm relapse rate after treatment with oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.48088129749657715" CI_START="-0.060881297496577114" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.12864754730484623" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.5194568268730784">
<NAME>Relapse rate 6 months after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.48088129749657715" CI_START="-0.060881297496577114" EFFECT_SIZE="0.21000000000000002" ESTIMABLE="YES" MEAN_1="0.55" MEAN_2="0.34" ORDER="50" SD_1="0.74" SD_2="0.48" SE="0.1382072832119642" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.807401279081692" CI_START="-0.12740127908169213" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.02" MODIFIED="2008-10-13 23:35:45 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.15394646077607002" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.4257294204519015">
<NAME>Relapse rate at one year after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.807401279081692" CI_START="-0.12740127908169208" EFFECT_SIZE="0.33999999999999997" ESTIMABLE="YES" MEAN_1="1.26" MEAN_2="0.92" ORDER="51" SD_1="1.31" SD_2="0.78" SE="0.23847442237127503" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5803730333529495" CI_START="-0.16037303335294956" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2012-09-12 10:19:35 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2664428764481067" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.1112915889888277">
<NAME>Relapse rate at years 1-2 after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5803730333529495" CI_START="-0.16037303335294956" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="0.86" MEAN_2="0.65" ORDER="52" SD_1="0.9" SD_2="0.79" SE="0.1889693056986785" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.6413202388344195" CI_START="-0.08132023883441936" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.28" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-004.04" MODIFIED="2008-10-13 23:36:07 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.12880118310312114" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="1.518846321594254">
<NAME>Relapse rate at two years after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.6413202388344195" CI_START="-0.08132023883441936" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="1.06" MEAN_2="0.78" ORDER="53" SD_1="0.98" SD_2="0.65" SE="0.1843504481125507" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.0805537489073003" CI_START="0.28278948796581055" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7670454545454546" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="0.3181789398128533" LOG_CI_START="-0.5485367384511407" LOG_EFFECT_SIZE="-0.11517889931914368" METHOD="MH" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6024197251262666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0" Z="0.5209239895063401">
<NAME>Proportion relapse free at 2 years after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0805537489073003" CI_START="0.28278948796581055" EFFECT_SIZE="0.7670454545454546" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.3181789398128533" LOG_CI_START="-0.5485367384511407" LOG_EFFECT_SIZE="-0.11517889931914368" ORDER="54" O_E="0.0" SE="0.5091130797240707" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" VAR="0.25919612794612795" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2008-10-13 23:36:44 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Days to next relapse after treatment with oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="1.8095636494376438E-32" CI_END="56.52645978702578" CI_START="-150.5264597870258" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-47.00000000000001" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-005.01" MODIFIED="2008-10-13 23:36:44 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.3735708926323448" Q="0.0" RANDOM="YES" SCALE="500.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.00000000000001" Z="0.8898044757145949">
<NAME>Mean number of days to next relapse after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="56.526459787025786" CI_START="-150.52645978702577" EFFECT_SIZE="-47.0" ESTIMABLE="YES" MEAN_1="236.0" MEAN_2="283.0" ORDER="55" SD_1="288.0" SD_2="176.0" SE="52.820592931109594" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2008-10-13 23:33:05 +0200" MODIFIED_BY="[Empty name]" NO="6">
<NAME>EDSS at first relapse after treatment with oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5287183745015125" CI_START="-0.46871837450151244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.01" MODIFIED="2008-10-13 23:33:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9061468564343972" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" UNITS="" WEIGHT="100.0" Z="0.11790004648409713">
<NAME>Mean change in EDSS at first relapse within 2 year period after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5287183745015125" CI_START="-0.46871837450151244" EFFECT_SIZE="0.030000000000000027" ESTIMABLE="YES" MEAN_1="1.56" MEAN_2="1.53" ORDER="56" SD_1="1.11" SD_2="1.16" SE="0.25445282588626084" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" NO="7">
<NAME>Proportion hospitalized for relapse after treatment with oral vs. intravenous steroids</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.693293696887105" CI_START="0.36651717510182086" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-007.01" LOG_CI_END="0.43028371471214727" LOG_CI_START="-0.4359056693798041" LOG_EFFECT_SIZE="-0.002810977333828425" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9898503533725426" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.0" Z="0.012721038693952129">
<NAME>Proportion hospitalized at week 1 after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.693293696887105" CI_START="0.36651717510182086" EFFECT_SIZE="0.9935483870967742" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="10" LOG_CI_END="0.43028371471214727" LOG_CI_START="-0.4359056693798041" LOG_EFFECT_SIZE="-0.002810977333828425" ORDER="57" O_E="0.0" SE="0.5088039319222147" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" VAR="0.2588814411395057" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="21.26188759357179" CI_START="0.16096877499412335" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.85" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-007.02" LOG_CI_END="1.3276018178110918" LOG_CI_START="-0.7932583610050641" LOG_EFFECT_SIZE="0.26717172840301384" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6214430475349451" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="38" WEIGHT="100.00000000000001" Z="0.49380621182629675">
<NAME>Proportino hospitalized at week 4 after treatment with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.26188759357179" CI_START="0.16096877499412335" EFFECT_SIZE="1.85" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3276018178110918" LOG_CI_START="-0.7932583610050641" LOG_EFFECT_SIZE="0.26717172840301384" ORDER="58" O_E="0.0" SE="1.2458037674638116" STUDY_ID="STD-Barnes-1997" TOTAL_1="42" TOTAL_2="38" VAR="1.5520270270270269" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2008-10-13 23:39:48 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Bioavailability of oral vs. intravenous steroids</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3289.629567327659" CI_START="-6614.770432672342" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4952.200000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.01" MODIFIED="2008-10-13 23:37:57 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="5.282210908178816E-9" Q="0.0" RANDOM="YES" SCALE="5000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="5.838028545135408">
<NAME>Area under curve for steroid absorption at 1 hour with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3289.629567327659" CI_START="-6614.770432672342" EFFECT_SIZE="-4952.200000000001" ESTIMABLE="YES" MEAN_1="899.36" MEAN_2="5851.56" ORDER="59" SD_1="422.91" SD_2="2209.16" SE="848.2658078344731" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-7396.33068931722" CI_START="-15975.94931068278" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-11686.14" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.02" MODIFIED="2008-10-13 23:38:16 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="9.332597294720571E-8" Q="0.0" RANDOM="YES" SCALE="20000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="5.339261458837986">
<NAME>Area under curve for steroid absorption at 2 hours with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="-7396.33068931722" CI_START="-15975.94931068278" EFFECT_SIZE="-11686.14" ESTIMABLE="YES" MEAN_1="3288.71" MEAN_2="14974.85" ORDER="60" SD_1="1103.93" SD_2="5697.99" SE="2188.718437951027" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="215972.56880065438" CI_START="-731488.6288006543" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-257758.02999999997" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.03" MODIFIED="2008-10-13 23:38:39 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.2862332012765805" Q="0.0" RANDOM="YES" SCALE="300000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="99.99999999999999" Z="1.0664214150510918">
<NAME>Area under curve for steroid absorption at 4 hours with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="215972.56880065438" CI_START="-731488.6288006543" EFFECT_SIZE="-257758.02999999997" ESTIMABLE="YES" MEAN_1="9392.19" MEAN_2="267150.22" ORDER="61" SD_1="1972.26" SD_2="639485.29" SE="241703.72646506815" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="99.99999999999999"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1564.6541836279102" CI_START="-26739.274183627913" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-12587.310000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.04" MODIFIED="2008-10-13 23:38:53 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.08128671402351013" Q="0.0" RANDOM="YES" SCALE="50000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="100.00000000000001" Z="1.7432685627329256">
<NAME>Area under curve for steroid absorption at 8 hours with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="1564.6541836279102" CI_START="-26739.274183627913" EFFECT_SIZE="-12587.310000000001" ESTIMABLE="YES" MEAN_1="18870.17" MEAN_2="31457.48" ORDER="62" SD_1="15527.19" SD_2="12409.46" SE="7220.522568402685" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-3449.4227575279474" CI_START="-25124.197242472062" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-14286.810000000005" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.05" MODIFIED="2008-10-13 23:39:12 +0200" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.009771865331904765" Q="0.0" RANDOM="YES" SCALE="50000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="6" UNITS="" WEIGHT="100.0" Z="2.5837992522983244">
<NAME>Area under curve for steroid absorption at 8 hours with oral vs. intravenous steroids (SA, outlier removed)</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3449.4227575279474" CI_START="-25124.197242472062" EFFECT_SIZE="-14286.810000000005" ESTIMABLE="YES" MEAN_1="18870.17" MEAN_2="33156.98" ORDER="63" SD_1="5527.19" SD_2="12670.12" SE="5529.3808090128105" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="6" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="12257.664272013384" CI_START="-17964.42427201339" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2853.3800000000047" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.06" MODIFIED="2008-10-13 23:39:27 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.711311703088785" Q="0.0" RANDOM="YES" SCALE="50000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.3700950069059499">
<NAME>Area under curve for steroid absorption at 24 hours with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="12257.664272013384" CI_START="-17964.42427201339" EFFECT_SIZE="-2853.3800000000047" ESTIMABLE="YES" MEAN_1="33472.67" MEAN_2="36326.05" ORDER="64" SD_1="12080.76" SD_2="16982.1" SE="7709.858135765441" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="14491.973383529503" CI_START="-16182.93338352951" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-845.4800000000032" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-008.07" MODIFIED="2008-10-13 23:39:48 +0200" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.9139612789890103" Q="0.0" RANDOM="YES" SCALE="50000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="8" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.10804338296659205">
<NAME>Area under curve for steroid absorption at 48 hours with oral vs. intravenous steroids</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intravenous</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours oral</GRAPH_LABEL_2>
<CONT_DATA CI_END="14491.973383529503" CI_START="-16182.93338352951" EFFECT_SIZE="-845.4800000000032" ESTIMABLE="YES" MEAN_1="35480.57" MEAN_2="36326.05" ORDER="65" SD_1="12661.02" SD_2="16982.1" SE="7825.375111231318" STUDY_ID="STD-Morrow-2004" TOTAL_1="8" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2012-06-17 01:46:53 +0200" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Immunological differences in cytokine titers</NAME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2012-06-17 01:46:53 +0200" MODIFIED_BY="Liliana Coco" NO="10">
<NAME>Changes in gadolinium enhancing lesions on MRI</NAME>
<CONT_OUTCOME CHI2="2.826429661995259" CI_END="0.28718788164754266" CI_START="-0.300662189947938" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.006737154150197652" ESTIMABLE="YES" I2="64.61967501097936" I2_Q="0.0" ID="CMP-010.01" MODIFIED="2012-05-31 22:18:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09272439860770476" P_Q="1.0" P_Z="0.9641670972695403" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.029078853754940723" TOTALS="YES" TOTAL_1="42" TOTAL_2="43" UNITS="" WEIGHT="100.0" Z="0.04492499067608676">
<NAME>Mean percentage reduction in gadolinium lesions on MRI weeks 0-1</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral`</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.09479531799020702" CI_START="-0.4147953179902071" EFFECT_SIZE="-0.16000000000000003" ESTIMABLE="YES" MEAN_1="-0.74" MEAN_2="-0.58" ORDER="66" SD_1="0.38" SD_2="0.44" SE="0.13" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="48.91238471673255"/>
<CONT_DATA CI_END="0.3795833910928669" CI_START="-0.09958339109286687" EFFECT_SIZE="0.14" ESTIMABLE="YES" MEAN_1="-0.29" MEAN_2="-0.43" MODIFIED="2012-05-31 22:18:09 +0200" MODIFIED_BY="[Empty name]" ORDER="58" SD_1="0.4" SD_2="0.42" SE="0.12223867019122295" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" WEIGHT="51.08761528326745"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0018808241429426383" CI_END="0.208702119839101" CI_START="-0.2399118317310391" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.01560485594596906" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.02" MODIFIED="2012-05-31 22:18:15 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9654078199274756" P_Q="1.0" P_Z="0.8915421335385586" Q="0.0" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="0.1363531184484492">
<NAME>Mean percentage reduction in gadolinium positive MRI lesions weeks 0-4</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.3283422421996475" CI_START="-0.34834224219964754" EFFECT_SIZE="-0.010000000000000009" ESTIMABLE="YES" MEAN_1="-0.59" MEAN_2="-0.58" ORDER="67" SD_1="0.62" SD_2="0.46" SE="0.17262676501632068" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="43.951440540309484"/>
<CONT_DATA CI_END="0.2796129305771676" CI_START="-0.3196129305771676" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="-0.44" MEAN_2="-0.42" MODIFIED="2012-05-31 22:18:15 +0200" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="0.46" SD_2="0.55" SE="0.15286654904910302" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="22" WEIGHT="56.04855945969051"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.8135661515924041" CI_END="0.8398872328947083" CI_START="-1.1132445574715577" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.13667866228842473" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.03" MODIFIED="2012-03-31 21:46:59 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.367068071502468" P_Q="1.0" P_Z="0.7838436742325066" Q="0.0" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="43" UNITS="" WEIGHT="100.00000000000001" Z="0.2743135479763908">
<NAME>Mean change in gadolinium enhancing lesions on MRI between weeks 0 and 1</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.9591971803845865" CI_START="-1.7591971803845863" EFFECT_SIZE="1.1" ESTIMABLE="YES" MEAN_1="3.15" MEAN_2="2.05" ORDER="68" SD_1="4.78" SD_2="4.44" SE="1.458800877433243" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="11.665809836541095"/>
<CONT_DATA CI_END="0.7390516523674615" CI_START="-1.3390516523674616" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.05" MEAN_2="1.35" MODIFIED="2012-03-31 21:46:59 +0200" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="1.63" SD_2="1.92" SE="0.5301381354776763" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" WEIGHT="88.33419016345891"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.17607638000781206" CI_END="1.0972594459551614" CI_START="-1.4664196070328472" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18458008053884298" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-010.04" MODIFIED="2012-03-31 21:48:04 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.6747670543222943" P_Q="1.0" P_Z="0.777769106246716" Q="0.0" RANDOM="YES" SCALE="1.6985227577780742" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="0.28222745721465076">
<NAME>Mean change in gadolinium enhancing lesions on MRI between week 0 and 4</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.9011794029892473" CI_START="-2.3011794029892467" EFFECT_SIZE="0.30000000000000027" ESTIMABLE="YES" MEAN_1="2.45" MEAN_2="2.15" ORDER="69" SD_1="3.87" SD_2="4.5" SE="1.327156735280351" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" WEIGHT="24.284362415805763"/>
<CONT_DATA CI_END="1.1331292993203086" CI_START="-1.8131292993203083" EFFECT_SIZE="-0.33999999999999986" ESTIMABLE="YES" MEAN_1="1.57" MEAN_2="1.91" MODIFIED="2012-03-31 21:48:04 +0200" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="1.99" SD_2="2.91" SE="0.7516103923032078" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="22" WEIGHT="75.71563758419424"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.3031946091690609" CI_END="2.030886269762715" CI_START="0.3670731649567291" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.8634140667773287" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="0.3076856034651477" LOG_CI_START="-0.4352473636224108" LOG_EFFECT_SIZE="-0.06378088007863154" METHOD="MH" MODIFIED="2012-06-17 01:43:09 +0200" MODIFIED_BY="Liliana Coco" NO="5" P_CHI2="0.5818866797097528" P_Q="1.0" P_Z="0.7364740501751001" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="43" WEIGHT="100.0" Z="0.33652626386050044">
<NAME>Proportion with gadolinium enhancing lesions on MRI at week 1</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.3267989910369313" CI_START="0.1925929699089809" EFFECT_SIZE="0.6694214876033058" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.3667588668045199" LOG_CI_START="-0.7153595696801206" LOG_EFFECT_SIZE="-0.17430035143780034" ORDER="70" O_E="0.0" SE="0.6356417261637282" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.40404040404040403" WEIGHT="47.13566817465562"/>
<DICH_DATA CI_END="3.5128926664625695" CI_START="0.33408681179346134" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" LOG_CI_END="0.5456648804851216" LOG_CI_START="-0.47614066796669774" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2012-03-24 21:12:25 +0100" MODIFIED_BY="[Empty name]" ORDER="46" O_E="0.0" SE="0.6002136371796382" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" VAR="0.36025641025641025" WEIGHT="52.86433182534438"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03978464820899064" CI_END="2.989454631669151" CI_START="0.4276132345068584" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1306327274847277" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="0.47559196689975497" LOG_CI_START="-0.36894886196570587" LOG_EFFECT_SIZE="0.053321552467024504" METHOD="MH" MODIFIED="2012-06-17 01:43:09 +0200" MODIFIED_BY="Liliana Coco" NO="6" P_CHI2="0.8419023247897035" P_Q="1.0" P_Z="0.8045278982047718" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="42" TOTAL_2="42" WEIGHT="100.0" Z="0.24749146249216944">
<NAME>Proportion with gadolinium enhancing lesions at week 4</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.7090565530750235" CI_START="0.2123567616419892" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.6729339061022971" LOG_CI_START="-0.6729339061022971" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.7905694150420949" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.625" WEIGHT="39.37644341801386"/>
<DICH_DATA CI_END="4.268674723037083" CI_START="0.3512507646029837" EFFECT_SIZE="1.2244897959183674" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.6302930624234717" LOG_CI_START="-0.4543827217132117" LOG_EFFECT_SIZE="0.08795517035512998" MODIFIED="2012-03-24 21:07:59 +0100" MODIFIED_BY="[Empty name]" ORDER="47" O_E="0.0" SE="0.6371439248336132" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="22" VAR="0.40595238095238095" WEIGHT="60.62355658198614"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2012-06-17 01:46:50 +0200" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Changes in T2 lesion number</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.15257816196527443" CI_START="-0.33257816196527445" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.01" MODIFIED="2012-03-31 22:09:43 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.467118805639149" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="22" UNITS="" WEIGHT="100.0" Z="0.7271749327289256">
<NAME>Mean change in T2 lesions at week 1 with respect to baseline in T2 lesion number between oral and iv</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.15257816196527446" CI_START="-0.33257816196527445" EFFECT_SIZE="-0.09" ESTIMABLE="YES" MEAN_1="0.09" MEAN_2="0.18" MODIFIED="2012-03-31 22:09:43 +0200" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="0.43" SD_2="0.39" SE="0.12376664259073128" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="22" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.5216895940211524" CI_START="-0.24168959402115245" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.13999999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-011.02" MODIFIED="2012-03-31 22:10:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.472205272195263" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="22" TOTAL_2="23" UNITS="" WEIGHT="100.0" Z="0.7188955688962304">
<NAME>Mean change in T2 lesions at week 4 with respect to week 1</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5216895940211524" CI_START="-0.24168959402115245" EFFECT_SIZE="0.13999999999999999" ESTIMABLE="YES" MEAN_1="0.36" MEAN_2="0.22" MODIFIED="2012-03-31 22:10:03 +0200" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="0.7" SD_2="0.6" SE="0.19474316723769988" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="22" TOTAL_2="23" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2012-06-17 01:46:46 +0200" MODIFIED_BY="Liliana Coco" NO="12">
<NAME>Proportion with HTN</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.348748734392863" CI_START="0.1758189396311256" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-012.01" LOG_CI_END="1.4039565265427096" LOG_CI_START="-0.7549343435157014" LOG_EFFECT_SIZE="0.3245110915135041" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5557141945833755" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5892192706647013">
<NAME>Proportion with HTN</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.348748734392863" CI_START="0.1758189396311256" EFFECT_SIZE="2.111111111111111" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4039565265427096" LOG_CI_START="-0.7549343435157014" LOG_EFFECT_SIZE="0.3245110915135041" ORDER="73" O_E="0.0" SE="1.26814318375447" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="1.608187134502924" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2012-06-17 01:46:43 +0200" MODIFIED_BY="Liliana Coco" NO="13">
<NAME>Proportion with rash</NAME>
<DICH_OUTCOME CHI2="0.7109885582230491" CI_END="2.2595860298529593" CI_START="0.2312238632191989" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7228210090324806" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-013.01" LOG_CI_END="0.35402888099767316" LOG_CI_START="-0.6359673470265322" LOG_EFFECT_SIZE="-0.14096923301442954" METHOD="MH" MODIFIED="2012-02-18 23:35:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3991163027475051" P_Q="1.0" P_Z="0.5767262070852077" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="0.558173075442791">
<NAME>Proportion with rash</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.1456674740237" CI_START="0.028277129425058976" EFFECT_SIZE="0.2982456140350877" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4977128117935357" LOG_CI_START="-1.5485646803819706" LOG_EFFECT_SIZE="-0.5254259342942175" ORDER="74" O_E="0.0" SE="1.201993528140841" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="1.4447884416924663" WEIGHT="23.406583386523206"/>
<DICH_DATA CI_END="3.4843104966380616" CI_START="0.2575852313029341" EFFECT_SIZE="0.9473684210526315" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.5421168492541347" LOG_CI_START="-0.5890790409531805" LOG_EFFECT_SIZE="-0.023481095849522914" MODIFIED="2012-02-18 23:35:58 +0100" MODIFIED_BY="[Empty name]" ORDER="49" O_E="0.0" SE="0.6644700654177412" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="25" TOTAL_2="24" VAR="0.4415204678362573" WEIGHT="76.59341661347679"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2012-06-17 01:46:40 +0200" MODIFIED_BY="Liliana Coco" NO="14">
<NAME>Proportion with hypertricosis</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.687669383617235" CI_START="0.03944967897540491" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.47368421052631576" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-014.01" LOG_CI_END="0.7549343435157014" LOG_CI_START="-1.4039565265427096" LOG_EFFECT_SIZE="-0.3245110915135041" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.5557141945833755" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.5892192706647013">
<NAME>Proportion with hypertricosis</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.687669383617235" CI_START="0.03944967897540491" EFFECT_SIZE="0.47368421052631576" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7549343435157014" LOG_CI_START="-1.4039565265427096" LOG_EFFECT_SIZE="-0.3245110915135041" ORDER="75" O_E="0.0" SE="1.26814318375447" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="1.608187134502924" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2012-06-17 01:46:37 +0200" MODIFIED_BY="Liliana Coco" NO="15">
<NAME>Proportion with anxiety</NAME>
<DICH_OUTCOME CHI2="0.004927835443852648" CI_END="2.441503649263015" CI_START="0.3690140617927183" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9491834272132491" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-015.01" LOG_CI_END="0.38765737775125264" LOG_CI_START="-0.4329570841319297" LOG_EFFECT_SIZE="-0.02264985319033851" METHOD="MH" MODIFIED="2012-02-19 01:10:56 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.9440356340220085" P_Q="1.0" P_Z="0.9138415801496043" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="0.1081942826264806">
<NAME>Proportion with anxiety</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.67331316667771" CI_START="0.17626384629593778" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.753836757265777" LOG_CI_START="-0.753836757265777" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.8856148855400953" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.7843137254901961" WEIGHT="29.625365802216344"/>
<DICH_DATA CI_END="2.8636450269799516" CI_START="0.3011004820204694" EFFECT_SIZE="0.9285714285714286" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.456919182498133" LOG_CI_START="-0.5212885492409356" LOG_EFFECT_SIZE="-0.03218468337140124" MODIFIED="2012-02-19 01:10:56 +0100" MODIFIED_BY="[Empty name]" ORDER="51" O_E="0.0" SE="0.5746040638298952" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="25" TOTAL_2="24" VAR="0.3301698301698302" WEIGHT="70.37463419778365"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2012-06-17 01:46:35 +0200" MODIFIED_BY="Liliana Coco" NO="16">
<NAME>Proportion with insomnia</NAME>
<DICH_OUTCOME CHI2="1.6379416552661434" CI_END="11.00914468897557" CI_START="0.6279860231113923" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.629370455277779" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" I2="38.94776430009569" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="1.0417535795269501" LOG_CI_START="-0.20205002211176248" LOG_EFFECT_SIZE="0.41985177870759377" METHOD="MH" MODIFIED="2012-02-18 23:36:14 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.20060817854583302" P_Q="1.0" P_Z="0.18577213585709376" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4178980118555028" TOTALS="YES" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="1.3231901950240383">
<NAME>Proportion with insomnia</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.925549770768965" CI_START="0.30001904406366553" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.7727286502660702" LOG_CI_START="-0.5228511770494704" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="77" O_E="0.0" SE="0.7610300037887249" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.5791666666666666" WEIGHT="53.537180138033726"/>
<DICH_DATA CI_END="30.720048571521996" CI_START="1.0762515535424475" EFFECT_SIZE="5.75" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="1.4874218980237746" LOG_CI_START="0.03191379135548623" LOG_EFFECT_SIZE="0.7596678446896304" MODIFIED="2012-02-18 23:36:14 +0100" MODIFIED_BY="[Empty name]" ORDER="50" O_E="0.0" SE="0.8549726667382795" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="25" TOTAL_2="24" VAR="0.7309782608695652" WEIGHT="46.462819861966274"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2012-06-17 01:46:32 +0200" MODIFIED_BY="Liliana Coco" NO="17">
<NAME>Proportion with dysgeusia</NAME>
<DICH_OUTCOME CHI2="0.1547014262769604" CI_END="13.628149987595322" CI_START="1.3583638654950874" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="4.3025558098294105" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="15" I2="0.0" I2_Q="0.0" ID="CMP-017.01" LOG_CI_END="1.1344369046453666" LOG_CI_START="0.1330161201725388" LOG_EFFECT_SIZE="0.6337265124089527" METHOD="MH" MODIFIED="2012-02-19 01:11:15 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6940825721689687" P_Q="1.0" P_Z="0.01311475500551154" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="44" WEIGHT="99.99999999999999" Z="2.480637829029252">
<NAME>Proportion with dysgeusia</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="60.16285997165224" CI_START="0.6667088487816369" EFFECT_SIZE="6.333333333333333" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.7793284732016752" LOG_CI_START="-0.17606378073534243" LOG_EFFECT_SIZE="0.8016323462331665" ORDER="78" O_E="0.0" SE="1.1486070893103677" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="1.319298245614035" WEIGHT="26.22801485530096"/>
<DICH_DATA CI_END="14.354699484169705" CI_START="0.9796443328895922" EFFECT_SIZE="3.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="1.1569941049667671" LOG_CI_START="-0.008931569511329326" LOG_EFFECT_SIZE="0.5740312677277188" MODIFIED="2012-02-19 01:11:15 +0100" MODIFIED_BY="[Empty name]" ORDER="52" O_E="0.0" SE="0.6848705126136028" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="25" TOTAL_2="24" VAR="0.46904761904761905" WEIGHT="73.77198514469903"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2012-06-17 01:46:29 +0200" MODIFIED_BY="Liliana Coco" NO="18">
<NAME>Proportion with hiccups</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="82.16475480197155" CI_START="0.12105854372842961" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-018.01" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4898494409043541" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.690548316968497">
<NAME>Proportion with hiccups</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="82.16475480197155" CI_START="0.12105854372842961" EFFECT_SIZE="3.1538461538461537" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.9146855635554856" LOG_CI_START="-0.9170045547296883" LOG_EFFECT_SIZE="0.49884050441289873" ORDER="79" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="2.766729205753596" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2012-06-17 01:46:26 +0200" MODIFIED_BY="Liliana Coco" NO="19">
<NAME>Proportion with hyperglycemia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.260466128217253" CI_START="0.012170668584238322" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3170731707317074" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-019.01" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.4988405044128986" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.4898494409043541" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.690548316968497">
<NAME>Proportion with hyperglycemia</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.260466128217253" CI_START="0.012170668584238322" EFFECT_SIZE="0.3170731707317073" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9170045547296883" LOG_CI_START="-1.9146855635554856" LOG_EFFECT_SIZE="-0.49884050441289873" ORDER="80" O_E="0.0" SE="1.6633487925728614" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="2.7667292057535957" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2012-06-17 01:46:22 +0200" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Proportion with headache</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="8.633419558112978" CI_START="0.7463771381518438" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5384615384615388" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-020.01" LOG_CI_END="0.9361828468240224" LOG_CI_START="-0.127041671681921" LOG_EFFECT_SIZE="0.40457058757105074" METHOD="MH" MODIFIED="2012-03-27 23:51:54 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.13580851118584408" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.4915829479886755">
<NAME>Proportion with headache</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.633419558112978" CI_START="0.7463771381518438" EFFECT_SIZE="2.5384615384615383" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" LOG_CI_END="0.9361828468240224" LOG_CI_START="-0.127041671681921" LOG_EFFECT_SIZE="0.4045705875710507" MODIFIED="2012-03-27 23:51:54 +0200" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="0.6245433452166391" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="24" TOTAL_2="24" VAR="0.39005439005439" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2012-09-12 10:21:29 +0200" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Proportion with mood disturbance (euphoria, depression)</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.447703687444529" CI_START="0.8719203886928713" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.8701298701298703" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-021.01" LOG_CI_END="0.9753262638470152" LOG_CI_START="-0.05952316682175748" LOG_EFFECT_SIZE="0.4579015485126289" METHOD="MH" MODIFIED="2012-03-27 23:52:22 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.08283030519138827" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.7344949264162643">
<NAME>Proportion with mood disturbance</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.447703687444529" CI_START="0.8719203886928713" EFFECT_SIZE="2.8701298701298703" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" LOG_CI_END="0.9753262638470152" LOG_CI_START="-0.05952316682175748" LOG_EFFECT_SIZE="0.4579015485126289" MODIFIED="2012-03-27 23:52:22 +0200" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="0.607875678162135" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="24" TOTAL_2="24" VAR="0.36951284010107543" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-022" MODIFIED="2012-06-17 01:46:15 +0200" MODIFIED_BY="[Empty name]" NO="22">
<NAME>Proportion with hot flashes/flushing</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="5.181677127693817" CI_START="0.5283078419776802" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6545454545454545" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-022.01" LOG_CI_END="0.7144703484357039" LOG_CI_START="-0.27711294278200443" LOG_EFFECT_SIZE="0.21867870282684976" METHOD="MH" MODIFIED="2012-03-27 23:52:41 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.38732380633996233" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="0.8644808469901104">
<NAME>Proportion with hot flashes</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.181677127693817" CI_START="0.5283078419776802" EFFECT_SIZE="1.6545454545454545" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" LOG_CI_END="0.7144703484357039" LOG_CI_START="-0.27711294278200443" LOG_EFFECT_SIZE="0.21867870282684976" MODIFIED="2012-03-27 23:52:41 +0200" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="0.5824609336777353" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="24" TOTAL_2="24" VAR="0.33926073926073924" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-023" MODIFIED="2012-06-17 01:46:11 +0200" MODIFIED_BY="[Empty name]" NO="23">
<NAME>Proportion with swelling</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.5867224110918252" CI_START="0.12123537221939581" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.43859649122807015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-023.01" LOG_CI_END="0.20050095581867308" LOG_CI_START="-0.9163706498195807" LOG_EFFECT_SIZE="-0.3579348470004538" METHOD="MH" MODIFIED="2012-03-27 23:53:04 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.20902249205685763" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="24" TOTAL_2="24" WEIGHT="100.0" Z="1.2562579358114103">
<NAME>Proportion with swelling</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours intravenous</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5867224110918252" CI_START="0.12123537221939581" EFFECT_SIZE="0.43859649122807015" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.20050095581867308" LOG_CI_START="-0.9163706498195807" LOG_EFFECT_SIZE="-0.3579348470004538" MODIFIED="2012-03-27 23:53:04 +0200" MODIFIED_BY="[Empty name]" ORDER="56" O_E="0.0" SE="0.6560559097555224" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="24" TOTAL_2="24" VAR="0.4304093567251462" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-024" MODIFIED="2012-06-17 01:46:07 +0200" MODIFIED_BY="Liliana Coco" NO="24">
<NAME>Proportion with pirosis</NAME>
<DICH_OUTCOME CHI2="0.3128856046587034" CI_END="2.669978948901261" CI_START="0.3572888200508229" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9767054971758211" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-024.01" LOG_CI_END="0.42650783724020774" LOG_CI_START="-0.44698057312361644" LOG_EFFECT_SIZE="-0.01023636794170437" METHOD="MH" MODIFIED="2012-02-18 23:35:37 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5759149504879215" P_Q="1.0" P_Z="0.96336010961215" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="45" TOTAL_2="44" WEIGHT="100.0" Z="0.04593744406954271">
<NAME>Proportion with pirosis</NAME>
<GROUP_LABEL_1>Oral</GROUP_LABEL_1>
<GROUP_LABEL_2>Intravenous</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours oral</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours iv</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.174807579932029" CI_START="0.31944399843974663" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.7138942056212481" LOG_CI_START="-0.4956052667711119" LOG_EFFECT_SIZE="0.10914446942506807" ORDER="72" O_E="0.0" SE="0.7104659772022196" STUDY_ID="STD-Martinelli-2008" TOTAL_1="20" TOTAL_2="20" VAR="0.5047619047619047" WEIGHT="52.15583798550897"/>
<DICH_DATA CI_END="3.0976765358621536" CI_START="0.16912683448130142" EFFECT_SIZE="0.7238095238095238" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.4910360660944573" LOG_CI_START="-0.7717874796727507" LOG_EFFECT_SIZE="-0.14037570678914674" MODIFIED="2012-02-18 23:35:37 +0100" MODIFIED_BY="[Empty name]" ORDER="48" O_E="0.0" SE="0.7417888018610257" STUDY_ID="STD-Ramo_x002d_Tello-2011" TOTAL_1="25" TOTAL_2="24" VAR="0.550250626566416" WEIGHT="47.84416201449103"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-10-26 10:54:08 +0200" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-09-12 10:24:14 +0200" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZAAAAKwCAYAAAC2+ylnAAAiAklEQVR42u3d4Zartg5A4fP+L937q73TaYIlWQYD314rqz2TBHAsacdA7D9//eDPnz8eL3rshj4Rf7gXf34mL17W+Rv1ufgTf7ipQHSkJFZIoO9R6D8dKAj+vHLfEH8gEBAIxB8IBAQC8QcCgQRWPCAGCAQSWPGAGACBgEAg/kAgIBCIP2wokMivR0e/LO3+5ekdf8F6h+PdXSCj16w6/sx+v/3/2Z/vHYsxgbxkBHKUJNnn3xJkBDJfpI9es/JLRVVcRnQEQiCDTl4hkG8jlshI5u+/Z99bHUFF9vftc9ttJLVrwfv2GUafz46Is333Kd4/7SMzcv+0nUpcEgheJZDK9kbfRLPbzI6wRvv7JJcdE+cNp7AqsVB9fmVczeYJgeB0gURlkEm4FQLp3GaXIO+Q3G+9BtJ5SrZTIDPtJxA8QiCRUwJnCOToRoCzBeIU1vUCycTCzgKpxDSB4FYCyTx/1ghk5fF0nLYjkHUCWVnYzxRIdvsEgssEkrnThEAIZFeBdAriSoG4BoJXCCR7wXiHayArvim6iL6nQGYuko+eP1MgTmHhlgL5GbyVW2Sz25sR3crbeEfbcw1kD4FU+qZyG292O9k7BzPHQSC4XCB4RRAoHhADIBAQCMQfCAQEAvEHAoEEVjwgBggEEljxgBgAgYBAQCAgEBAIxB8IBAQC8QcCgQRWPCAG3iaQM5cRzayrMbvfzNxUOwb2imMikPXH+8Z8IhAjkEsCfmVwEQiB7Hi8T8wnAjEC+c+3lu5lOo+WAJ1dHjRy3NnjOGpX5rOoftaRJU+fIJCnLVH8tnwiEAIJDYEjRTG7TOeqmU2zqyJGjrt7qd/IZ909UtpVIE9aoviN+UQgBLKkKF4V8B2nsFYsa7t6ydM7j0BmP9uz+7IikKfmE4EQSOobUddyoZnnZvZLIPcTyF2XKH5jPhEIgbR8EzvzG1PlWyyB3HcEUu3bLoF0nMJ6aj4RCIEQCIEQCIEQCPoEMjukXhnw3RfRVwtkdmnVtwvkLksUvzGfCIRA/hMsK5bpzCzRufK2w8hrI9/YZo8pu2TpWwRS+WxnYrTSV5kvJ0/PJwJ5sUCwVSfdevuKB8QAgeCiZCIQEAgIBOGE6vylOYGAQEAgIBCIPxAIJLDiATFAIJDAigfEAIFAAiseEAMgEBAIxB8IBAQC8YdbC2TVawURgYz+/obVIe/QZgIBgYBACET8Ya1AqvP1ZP/+c9vVuYxm30sg++z7ycsLZ3JjNie+fSbiD8sF0j1jaPcynZn9XTE9CIH0j0Duvrxwx2y3s0vfij9cIpBIR2eX+5wt8l2r0QmCe57CutvaLCu+dM3mIIHgUoFklxedXS5zNGQf/d1pLAJ5kkCqS/yKP1wukNnTRjOvzySrACWQt4xA7liY5ecLBbLDcJxACIRACAQ3EMjs0quzFyRn9ucaCIF0xZRrIASCgEB+Jkx16dWjWxW/BXvnUrDfnhOw9xDIE5cXzlzDy95mfNffkcjHhwoEBKJ4KHY+UxAICKTh2OQLgYBAQCDh43Pqk0BAICAQiD8QCAgE4g8EAgKB+AOBQAIrHhADBAIJrHhADIBAQCAQf3ipQJ4y548E1ncQAwQiwCSwvoUY0HeZubC+Pde11GZ1udvuObUk8B77no2vaIx0xzsI5PUC6Vxe9tPz2bVFosczO6uvBN5j37vFX2Z/CiKBEEjzErFnTYPdvYaDBN5DINV4ODv+QCAEMhiWR5eInV2+lkDeK5BR/J0tkFG8O4VFIAQyMYLoPAVBIASyUhAd8acgEggWCeTKUwgEQiAEIv5wsUC6LypmE7i6v9ljk8B77Puu8acgEgiB/Eq8jtsas8uPrhqBjI5NAu+z713ir7I/EMjrBSKAtd9nDzEAAkmMUCSw4gExAAL5GrBOORAIxB8IBAQC8QcCAYFA/IFAIIEVD4gBAoEEVjwgBkAgIBCIPxAICATiDwQCAoH4A4FAAiseEAMEAgmseEAMgEBAIBB/IBAQCMQfCAQEAvEHAoEEVjwgBt7UdzpQ8joG6HuUBaIjJa9jgT5HWSB/d6jHex47FhQP8YebCsQ3IUD8AQQigSH+AAKRwBB/AIFIYED8gUAkMCD+QCAS2IcA8QcQiASG+AMIRAJD/AEEIoEB8QcCkcCA+AMIRAJD/AEEIoEh/gACkcAQfwCBSGBA/IFAJDAg/gACkcAQfwCBSGCIP4BAJDDEH0AgEhgQfyAQCQyIP4BAPiewh8eVD4BA4Bs0AAIBCAQAgYBAABAICAQAgYBAABAICAQAgQAEAoBAQCAACAQEAoBAQCAACAQgEIBAgLw4zOkEEAhAIAAIBNdIBACBAAQCgEBAIAAIBAQCgEDwNIkAIBCAQAAQyBWF1MM65uLe4y1xLwt8C4c+9xmg1Od6XxJB32s7Sn0vAiQRxIA2oxQDokAiQQxoMwhEIkEMaDMIRCJBDGgzCEQiQQxoMwgEEgliQNyDQCQSxIA2g0A2T6TRa7493/3r5zv+gvoOx0sgxzH7n18vN/+iX1wTyGMFMgruo+c7g+yuAUsg92/zv365/OF9M5+fuCaQxybSP7/WHAiiK6m+fbOLfOP7eSyZ90af+/QtdLS/T5/DjnNREUj8dZVYF9cE8upEqpzCyp6+GiVmZaSU3Wbmm2Zkf5+ScMfCTSDr8kNcEwiBTBb/sxKtc5uV9862gUDuE/dnfjES1wTyOoFc8U0tMgq6MtGcwnpW3IvrveOaQAik/ZvayuPpGHURCIGIawJ5vUB2PYUl0QhkJjbENYHgAoHc4Vxx9mJjdFhf/UwIhEDENYG8UiA/Ay16bjRye2H3Mcze7jjanmsgzxKIuHYbL15ePCAGxD0IRCJBDGgzCEQiQQxoMwhEIkEMaDMIRCJBDGgzCAQSCWJA3INAJBLEgDaDQCQSxMCa4vCAX0uDQBQPiIGLBFKZcBAEAgLR7uRn8a3oPvVxl1i7+v0EAsGl3UYgF41ACIRAXlk8KnPtdCzBOdpm9v2f3iup3iGQ2bivrOY3M5lhJFbFOoFsXzwySZBdEjObVLNJOZpNVAy4C6sSS5UZcGdjVawTyG0Tqfpch0BWPi8GCKRbIGKdQF5fPCpTUFeX4Myer+58vxggkGgsZUbZqwQh1gnkdsWja83lyjFcsaqbGDACGX2xukogYp1ACIRACOSGAtnxFJZYJ5DtE6lrycyzksqFRQLpEsjKi+iR5WHFOoHcsnjM3MZ79PqOZTbd2kggZ8R99228kVh0Gy+BKB4QA9oMApFIEAPaDAKBRIIYEPcgEIkEMaDNIBCJBDGgzSAQiQQxoM0gEIkEMaDNIBBIJIgBcQ8CkUgQA9oMApFIEAPaDAKRSBAD2gwCkUgQA9oMAoFEghjQZhCIRIIY0GYQiESCGNBmEIhEghjQZhCIAgJ9r+14Td+LAMkEfe4zQKnP9X73kM7jNQ+I+7fHvSyAb6EAarnvIwCBACAQEAgAAgGBACAQEAgAAgEIBACBgEAAEAgIBACBgEAAEAgIBACBAAQCgEBAIAAIBAQCgEBAIAAIBAQCgEAAAgFAICAQAAQCAgFAICAQAAQCAgFAIACBACAQEAgAAgGBACAQEAgAAgGBACAQgEAAEAgIBACBgEAAEAgIBACBAAQCEAhAIAAIBAQCgEBAIAAIBAQCgEAAAgEIBCAQAAQCAgFAICAQAAQCAgFAIACBACAQEAga+t/jPQ8CAYFA32O6z/U+FBHod5T6XgRAIYE+RykGRAEUE+hzEAgUE+hzEAgUE+hzEAgUE+hzEAigmECfg0CgmECfg0CgmGC7Pv/0msivm0uF7GAbmX3860dyg/d0xf1d84dAQCBY0ufVor3iOKrbIxACAYHg5D7/51fKxVHKaNQy+vvR899elxVI9piiozECgWICfd70mkzBj7y/SyCd2zYCgWICfd4gBwIhECgm0OevFMhw+vMvfyMQKCbQ5w8USPS6RuZ6DoEABKLPi6+ZuUPrTqewOvZDICAQEMiGAjkaVbgGQiAgENxYID+LfOX0z+j22dkRyOxtvN+2QyBQTKDP8egYEAVQTKDPQSBQTKDPQSBQTKDPQSBQTKDPQSCAYgJ9DgKBYgJ9DgKBYgJ9DgKBYgJ9DgKBYgJ9nt7WGSsZyhECgeTAAwXyxLgjEIBAEOjzyNxVR2tnHK2zMRq5RJe4DRXHRBtG+yIQgEAw6PPIjLQREWSfy87am53oMdOGyCJSBAIQiD5PvnZUnCOv7xDITHsr+yIQgEAQ7PPKtOazAokuJ5u5SF9pA4EABIJin2eFsGoEMitAIxACAYHgxD7vKK5XC2S2DQQCEAgaBNJ9CuuKi+izp7BcRAcIBIkCHFkyNvL6T8+PCnX3bbzVUZTbeAECgT4HgUAxgT4HgUAxgT4HgUAxgT4HgUAxgT4HgQCKCfQ5CASKCfQ5CASKCfQ5CASKCfQ5CAQCCfo8857qdPBdxxz9NbocIBAQCDYTyNXH3H0sBAJIHjT0eWTuqk//X5nz6mjf0eV0Pz032u/MMY4+r+h+MzMiEwgIBNv3eWX23IpsoqOKzHZWbjv6OWZm/iUQEAgeLZBKwc2+Nnqc2SKfWXSq8/rOqmnqCQQEAgKJFLbBKZ+qQKKnk6KnsAgEigmB6PNNBNJxKiz6msrKid0C+fnvs/OQQEAgeIxAuq9TzC5jSyAAgWBCINGL6B2FP3NBelYgs9uubDf7NwIBgeB2fV69jTdbvLPL43668+vo23tmmdrsMUa3+/v5q++8IhAQCPS5z5ZAsEEABb4dQZFD/HMkEBAICASlPLrVces+dAU/CAQvy30fAwgEBAICAYGAQEAgIBAQCAgEign0OQgEUEygz0Egaz5Qj9c8COT479HPaGZG2d36YfZ4rn4/gfhGBn2+hUDO+BwJhEAUEuj7F4xAvq2jEZljKvreb6+NnjU4al9kH5WZdGfmwYrM6UUgCgjEwK0Fkp1F93eBrLx31DfVWYBXTxLZ9X4CUTwgBh4pkGjRX7kiX5dAuo69+3kCUTwgBh4hkJ/fkGdX+os8H11OdnRzROR4Vwri6PgIRPGAGHiNQCqjiJmVALMjnyPJXCWQmREUgSgeEAMEcpFAdjyFRSCKB8TA6wQycxG9Kp+KQFZeRB+dgnIRXfGAGCCQQYGbWSr20/O73sY7alv2+cptvCtjk0BOLB6jzu/o6NF2MvvpOk3whkJMIHhjPxHISR0UvRC38he52W0TiGKqzfqJQC7uoMzQMnvbYWWYe/SL1epFw+yvhEfbuFtxIhC8tfaJgoWJlJ1YruuCX+T9XQLp3LYRiDaDQCQSgRAIgYBAUE2k7N0Qs/d87yaQ7l/4KqbaDAJ5RSJlr29URydnCyR6XWPFL3wVU20GgbxGINFFiGZvA951BBJ9vVNYBAICIZCmkcpVAjkaVbgGophqMwhkI4FUlkkdXVOYGSnNjkBmb+P9th3F9Hlt7pqOHQTimxjEwIvbTCAEonhADGhzeGLDo5sysqPR36+PjNazz1fOBFS2fceRt+qneEAMXCKQb6/Jzqg7cw0u8nxlksXKto1AFA+IgVe3+dNI4qiIzk7x03EbfUQSq+R09xhQ/RQPiIHHCSR6C310ivkugRxtm0AUD4gBAtlwBBIp6tXRycw65U5hKR4+BDGgzTcSyMw+CIRAFA+IgYVtziwze8U1kMpSs10CcREdBAICaRRIZp2azEhodinYmdt4R+13Gy/aO70aUHcKvCcWWwLBGz9TAtlcIE8MPALRZhAIgsPrzC9Wq8Pq0Txbo+H7MEgaf3UbOR1RnVfrqlMCBIK31j5RsCiRZn+x+un1kec6L+Kt+NVt56+KCYRAQCCvSaTKD46yhX71L2F3uKXx22JXR3JRTLUZBHK7RKpMaz4rkOhyspmCXWlDp0BGx0AgBAICeVQizdxP3jkCmRXg1SOQyDEQCIGAQB6TSF1z5lwpkBUTx636URiBEAgI5LEC6T6FdcVF9NlTWJGL6NljyLZJMdVmEMgtEim6ZGzk9Z+eHxXZ7tt4q6Oo7G28lc+FQAgEBCKRIAa0GQQikSAGtBkEAokEMSDuQSASCWJAm0EgEgliQJtBIBIJYkCbQSASCWJAm0EgkEgQA9oMApFIEAPaDAK5ZyKteu1hB0t0xfTkNmdmQrjis+tc0uDN8UIgDxYIcRDIFW3unmCTQAjEN7HA3FbRJVwj39yOlsfNbHP0nugIqGM53J2TjkDWCmRmPZrsqpmjPM3kcfT9BEIg4SCsJtrs1OjZ5WIj4jhzOdydE49A4q/tnuI/Oit15+zVK2ekJhCJNPVNK5Og1cWsuiS201oiBEIgZy0B/dQ4JpAbCiQzPM+exrq7QEZL8xLI/m3uGElHl2iuxObqOCUQLBNI55K3bxiBPOHb+JsEUom56n6uFEjHZ0AgBLK0gHZcAyEQAjmrzV2ndqunfQmEQB4lkNHQNvL86FvX0wXiFNY92tyx7n0lTjouos/maXb7BEIgw6F1dIna0S2IM8vDVq6pzC4dm9n26PNxG+99vjhFr1nM3g7ecRvvbJ5G2uM2XigeEAPiHgQikSAGtBkEIpEgBrQZBCKRIAa0GQQikSAGtBkEAokEMaDNIBCJBDGgzSAQiQQxsLw4TE4xAgIBgeDFAslO9gkCwQOKR/fU8SuOY3bK+l364tPiWG94dMREdnYDsicQAtlMIFcdR/cxXC0QI5D5z45ACIRA/opPslZd8rVr+9+SuLrMbHTen+iyu5l5hwikXyCZNkfnTvs2YovEbSUGjvY3em0l7iN5kW1PddsE8mCBjIr6zHohmfdXZjHNiCjz7bNz/wRybpuzAjkrBrLTr1e/rGXyYkUenx2LBLLBCGSH5zvXOZ85hXXGMsAEck7cf/tvpQDuuH5HV1zeed0cAiGQ1Cms7uU7Z9Ys2enOIAJ5vkAiNxFEp7Dv/lLmFBaBbCWQ1d/eZgSSPR1AIARyxgqCVy2pe2UsEgiB3EogroEQyI4CmYl7AiGQcHFcffHsCRfRZ7ZPIHu0eWbUuOKC9eprIDPLU6+8QE8gD0ikoyVrI4FRvWV299t4o6/NLgNMIPcTyEwMVPIichtvd9yvuC052iYCuWkiKUpiQJvx5BgQBQQCfaXNIBACgWKqzSAQiQQxoM0gEIkEMaDNIBBIJIgBcQ8CkUgQA9oMApFIEAPaDAKRSBAD2gwCkUgvb/sVv44VA+9q8+qVN4mSQBSPC9r+ps+FQJ57nARCIJcW0Y5lLnfdbnbeoMzSnYrpPducXao5EjOj/WRitHMut9lcJBC0Tee+ckbcVdvtnmn3rklGIMdxkZkleiSIo+c7ZsCeifFMvhEI0kExs8xlNWhXbnf1Wh8E8vwvTp1filavJdKZ4wSC6SFuZegbWV5zxXYJhECeIJDOGJ/NcQLBdBHNPjfzjWhmuwRCIFcJ5Oe/uxdnmonxzhwnEAJpLbgEQiAEsrdAdl5ulkAelkgzy1y+5SI6gTwj7mfibOZvV19Ez+Q4gSD0jaNjmcuj53a8jfcoWTNLdxLIfb84Zft5FHuZkcpVt/Fmc5xA4IdGIBD58Nq419uKB8QAgYBAFA+IAQIBgSgeEAPaDAKRSBAD2gwCgUSCGBD3IBCJBDGgzSAQiQQxoM0gEIkEMaDNIBCJFHzfiinhj177pimnFdN92rz6c+rIxc5jOCOvCYRATtm3+/YJhEDuEQsEIpH+/wEH5gTKzOfz6f+z+/j0vuwcRCCQSNwfvSczL1VkadzoKoaRb/+zx3VWXkc+RwK5YSJlZv6szihakUZm3wRCILNxv3L1wOiU71mBdM1afXZenx2PBHIDgax4bWbKafIgkNm47yp8XcsadG53p7wmkIclUnT5TAIhkDcKJHIKtbr87EqB7JbX0VPRBPKQRNpZIJFTASCQFSOQ0bay37wza3rMjEB2yesrYkCFIBACIZDtBNKxNC6BEMijEmn3i+gEQiDdcd91ET17CutMgbiIjiXFY/fbeKPvBYFU435U4KvLy86so94xsnEbL4HcpnhcUaAIxGf1hDbvfJx3jxsC2TAIrhySEojPikDOOw4CwZIguGpI+nPfIJA7t3nHOL4yrwlEIkEMaDMIRCJBDGgzCMSHKJHEAIGAQCCRIAa0GQQikSAGtBkEIpEgBrQZBCKRIAa0GQQCiQQCAYFAIkEMaDMIRCJBDGgzCEQiQQxoMwhEIkEMaDMIBBIJBCLuxT2BSCboe21Hte9FgGSCPvcZoNTner97SOfxmgfE/dvjXhbAt1AAtdz3EYBAABAICAQAgYBAABAICAQAgQAEAoBAQCAACAQEAoBAQCAACAQEAoBAAAIBQCAgEAAEAgIBQCAgEAAEAgIBQCAAgQAgEBAIAAIBgQAgEBAIAAIBgQAgEIBAABAICAQAgYBAABAICAQAgYBAABAIQCAACAQEAoBAQCAACAQEAoBAAAIBCAQgEAAEAgIBQCDYWBy/HwAIBCAQAASCcyQCgEAAAgFAICAQAAQCAgFAIHiaRAAQCEAgAAjkikLq8Z4HQCDwLRz6HCAQhQT6HiAQBQRiACAQxQNiACAQKB4QAwCBKB4QAwCBKB4QAwCBKB4QAwCBKB4QAwCBIF88Mr9ejhShTKGqFrWuYji7nZXv7y74BAICwaWF6mlFbWeBGIEABLK1QLLy+D1K+fnf3387et+3/UfncPr5/O9j+PTeyP6/ve9oO5m2Rt4/00YCAQjkdIFkJt/7VjCrRfnotZnimjmG6P4j2+l8/0wbCQQgkC1GIJnTXdn3Zwt4dhvZ7c5up/P5zvcSCEAgywWSfW1VIN9GOZ2nsHYQyNGIjkAAAiGQpECyp7jOKPxnjTC6RnsEAhDIdgJZfQqrq7gTCIEABLK5QCoX0TOF7+i0zsxF9OwxzB5r5Pns9gkEIJBbCeRnIYteexjdhpq59fWMayBH2525TXf0/IrbeAkEIJCtBAIxABAIFA+IAYBAFA+IAYBAFA+IAYBAFA+IAYBAFA+IAYBAoHhADAAEonhADAAEonhADAAEonhM77c6dfun1yuGBAIQyIsEMnM8ih+BAASyYfHIzFX1bTSQWTL2aL2M6N9Hc0lFtisGAAJB40hgdobZo+ezM+9GXj9qV8ckhAQCEAiBBP8+OwtsRSCZ7cw8RyAAgWAzgUSWcY0IJLP0bfS5o2VmxQBAILhQIJUFm7Lbje7T3VoEAhDITQRy9TUQAiEQgEA2EcjsMq7VU1iV/WRl+PZCSiAgELQXj85lXDMjkKPbdUevz4jB9Q8CAYHgpOKh0IgBgEBAINCvEPs+AgIBgQAEonhADAAEonhADAAEonhADAAEAsUDYgAgEMUDYgAgEMUDYgAgEMUjtb+V+1cYfU4AgRAICAQgkDsVj8j6G7///ml52k/bi7z+6H2j4/wmq7fPe0UgAIEsLx4zS8Vm1++YWTmwsuaIokkgAIGcKJCIXGYLfsf2Kq8TAz4bEAiai0fm1NBKgYyWnnUKi0AAAtm4eMys9Nc9AokeZ2YUJQYAAgGBEAiBAARyZfHoXGv8zGsgLqITCEAgGxSP0TWDylrjlSVo3cZLIACBPKx4KDxiACAQxUPhEQMAgWB98XAaSAwABALFA2IABALFA2IAIBDFA2IAIBDFA2IAIBDFA2IAIBAoHhADIBAoHhADAIEoHhADAIEoHhADAIEoHhADAIFA8YAYAAhE8YAYAAhE8YAYAAhEAYG+BwhEIYE+BwgEsYLi8Z4HQCCAb+IACAQEAoBAQCAACAQEAoBAAAIBQCAgEAAEAgIBQCAgEAAEAgIBQCAAgQAgEBAIAAIBgQAgEBAIAAIBgQAgEIBAABAICAQAgYBAABAICAQAgYBAABAIQCAACAQEAoBAQCAACAQEAoBAQCAACAQgEAAEAgIBQCAgEAAEAgIBQCAQRAQCEAhAIAAIBAQCgEBAIAAIBA8Tx+8HAAIBCAQAgeAciQAgEIBAABAICAQAgYBAABAIniYRAAQCEAgAArmikHq85wEQCHwLhz4HCEQhgb4HCEQBgRgACETxgBgACASKB8QAQCCKB8QAQCCKB8QAQCCKB8QAQCCKB8QAQCDIF4/Mr5cjRShTqKpFrasYzm5n5fu7Cz6BgEBwaaF6WlHbWSBGIACBbC2QrDx+j1J+/vf3347e923/0Tmcfj7/+xg+vTey/2/vO9pOpq2R98+0kUAAAjldIJnJ974VzGpRPnptprhmjiG6/8h2Ot8/00YCAQhkixFI5nRX9v3ZAp7dRna7s9vpfL7zvQQCEMhygWRfWxXIt1FO5ymsHQRyNKIjEIBACCQpkOwprjMK/1kjjK7RHoEABLKdQFafwuoq7gRCIACBbC6QykX0TOE7Oq0zcxE9ewyzxxp5Prt9AgEI5FYC+VnIotceRrehZm59PeMayNF2Z27THT2/4jZeAgEIZCuBQAwABALFA2IAIBDFA2IAIBDFA2IAIBDFA2IAIBDFA2IAIBAoHhADAIEoHhADAIEoHhADAIEoHqccV3V699G24PMAgeDhApk5ZgXS5wMQyAWFOjpX1bdv+qO5pr6tjzFaIjfynsi2Rp9JZj4wAgEIhED+6p9h9lthjr4/Oztv5PWjtndMVEggAIG8XiCVEcisYDLv7dpW90y3BAIQCIEUi2t1GdeKQDLL40afO1qKlkAAAiGQRQKZ+XY/OzLInPI6WsPjzTEAEAguEUj38yuugRAIgYBAcIJAZpdxXXkKq3IsWWE+udgSCAgE7cWjcxnXygjk6L1Ht+tmthURqdt4AQLBZPFQaMQAQCAgEOhXiH0fAYGAQAACUTwgBgACUTwgBgACUTwgBgACgeIBMQAQiOIBMQAQiOIBMQAQiOKR2t/K/SuMPieAQAgEBAIQyJ2KR3Qdj59/71iq9ug4Rs+PZPXkOa0IBCCQLYrHzDKw2Zl0z1g3xMiHQAACuUggEbnMFvyO7VVeJwZ8NiAQNBePzKmhlQIZLSvrFBaBAASycfGYWcWvewQSPc7MKEoMAAQCAiEQAgEI5Mri0bmO+JnXQFxEJxCAQDYoHqNrBpV1xCvLy7qNl0AAAnlY8VB4xABAIIqHwiMGAALB+uLhNJAYAAgEigfEAAgEigfEAEAgigfEAEAgigfEAEAgigfEAEAgUDwgBkAgWFo8VhWXOxStjmOszjVGIACB3LpIvn298quX+yUQgEAeI5Bvqw5ml6LN/n10/KO5sKrL5UZXYTzaR2Y+LgIBCOQRAjkqtkf/Hr1/JKdMYYtO3Bg9hm/PR9eBH+2jo80EAhDIbQUS/XfHOh/VaVa6pFSZNv6KNhMIQCCPE8jRUrRH++06jZWZbn70/uqpqeyU8gQCEAiBTJ5++vnvyHWK6ggk8/7RKa2Z0QmBAARCIEWBrLoG0vk8gQAEgosEUjkllJXQ7DFUBOIiOkAgBNIokJ8F+dupp6PbeKOF7eg92eVyK+8/ak9kfwQCEMjjBKKwnP+Z+B0IQCAEQiAEAhCIgqi4/P9zeOrULvoYBALFA2IAIBDFA2IAIBDFA2IAIBDFA2IAIBAoHhADIBAoHhADAIEoHhADAIEoHhADAIEoHhADAIFA8YAYAAhE8YAYAAhE8YAYAAhE8YAYAAhEAYG+BwgECgn0OUAg6wqKx3sewNv5HyWs1BKGIU3QAAAAAElFTkSuQmCC</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-10-26 10:54:08 +0200" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAWkAAAHrCAIAAACCYfvKAAAadUlEQVR42u3dwY4dxfXH8SshIRZeeOEn4BlmhSxWsOKd8NILS3jpt0A8QgTJElixQyR2BF54MSS7QKzOHRz9/5OZ7nu7+/apqlP9+WkUWQP5+VL31LfOqa6uczgQEa3TQES0RNhBRNhBRNhBRNhBRNhBRIQdRIQdRIQdRIQdRIQdtPtYcRaZsIMWRcmcXxJ2EP1/iKz+p4QdRETYQZclIGKGsIPWgEO1QthB2EHYQdhB2EHNxgpwEHYQEXYQEXZQ07HiWDphBy0KlNt/EDOEHbSGHfBB2EHYQdhBpfAhZgg7iAg7iAg7qKlSRRtjwg4iwg4iwg7KESsKFsIOWhQoZ39D2EGEHYQdFIAPMUPYQfNCxDNawg4iwg4iwg4iwg4iwg4iIuygC2PFnYOEHbQoUKb+QNhBhB2EHYQdhB3UUKw4VErYQUTYQUTYQa3GyuifCTuIZoEDPgg7CDsIO6hMrHjOQthBRNhBRNhBGWoWYSMeBAHNChSDQNhBbbFDOoMdBB9r4m/OLwk7KHOgbJognHYQlthBRNhBFFkNiUbsoF2ULZuDQ7WCHdRzarDt9MYO7KAdsWPDGY4d2EHYcVEUAgd2UP/4EDOEHUSEHZQ6Ch1Lxw4yw9eVQoP9Duyg/gIl2tl2KXbQ4jUcO7ADO2jWiM/55T7xIRqxgxZPv8a/CDuahB3UUNJB2EE9Z+lBF/8MMTeDEHb0D45Eq7o4IezAjrWBIjsg7MCOZsEkQrCDzoy7gmXQ6RY7aD/pEnYQdtDKsmLbsLltJRqxg5ZNRYNgywM7aO4y681Rwg5az44hz3ap1ICwAzvWb0nYmCDsaAIfSZ/RChsxjB2EHYQdFB0rAfsdnrNgB81avXM9lYz+bMIPO6hz3mEHYQddWlPEnSsl7KA6ewfpsgPnSrGD1s/DPV90TNhBPbMDPgg7mpuHGQ+kb77foWDBDlo8A3f+FTh1hh1E2JFjqDeZ9dhBi5Ombac3dpQHxybjjB1UJ/JOlHJGGztI5BF2kMjDji6qzq2+PuyovHeQ62jpth9YT8keYthAVFnDibCDsGOz0TA+0UnuJvkddsBHzZrFSblaUWe/o591YLfZgfBL+g1iB6ksfIPYQXky3jLOFFd1YkcnewdV6qytQlBGkziGDYT8v8vRsAWLHWZLQ592808eMcNHrVx3oGbBDvOwMu9EHXb0s98RPcPl/9iBHbuIjEQrbdDNIEPCvr/YQbRmem9LOu/+2u/obZ6U6ZOUrvMLdqQkkYGwhmMHYcfuKs/ssyVuF3bb2246q1nsd+T+8jZ/1LI5O7zt2uuKJe/wLeZeaZ2yxQ6i5jIauVIcPgxo/W8xy/gX68+yuXPEyRGMxo7esvREOynFxtl2aSCSDEQf7Ihbacv0dkr0mUUddjSRRrY/W5KewnAmXc1CDWUHWXhHQXUxdvSPj52fSSf7HT2nkabKoONczqgzoFba9WWzr3LPUScIOmFH9EorSEQddsg7WmFH+XOlog47VPid4OO+c+iJVfhw9w+VplLJaqh9Z8KObvPSRLMl+oQ+cGBHh0lBojU8V67kzpGZw4IdVGKlNQ87y0nlHVQno4n2FJbYQaem+pD2dq8Nx2HOL6m1LxE7an6F2S8HbHa/o3yilzQ5xQ7sqFMT7TlnTJcrqVmwg6qttEPmPRrs6DOmDUiuIsuAYIeVtmfeRfeyyFKtBFWd2GFhWemc4jxb3OMhVSd2VJ7kQff3pWBHgTMpbo3Hjm7BkW6lLZB37PwbxA6qEHnuwig8c3YLDuywarUUhXiHHWTVaqFmcX/HiWzUcxYqt9La3y2TK5XBtHvDulpjI0495ureloUdGbtk6ynZVbVy+pc7YUfG/d0+bqvGDpVF+rwjb/6YusOOmoXK7XcAxyg+PKMlqsy7raikpyR2ULvV8s7z/w5yUvsdVGilTfdeWdA7OEkzGvd3UCtLVsu7sHosYIfssf5KW3402q+z4AM7+tk7sNL2wbtEmaPw6oQdBVbaRH0honclvCmDHR3iI/oDB51Jz77viB2UMnucCuIUp7DzZmHpwKFmoQrrYUZ2DHEPFzI/o92q6sQO7Fg5bdpPEOwch9IfO5rIHlM4Z8mlCTtkBzsdDeNcAB9qFuxInys57ZI7dzYQ/e1KDMFXe2W8N4yww35HoZq2ADsynuCS1GBHzwVtaHbQ/rnS6Ok9Ohq7mkrYgR3d7iCU34XFDoqNZt3bTiAv9Z3j6dIx7CC5UonZcpbRu8rCsKOhVQs7Nq+zdltQYEenJWJAzdLNexaDvhBJ8IEdPawAfSA1omDJWA2VXLewg1LmSoWTGrcZqln6nJCbO0fkqCaP/3zsaKjC3/m50ojsILpn+JDz5rdtk0fsqM+OIecNPY1/5uie4akruE1GGzuwY+WEaX80hpwn5YrVWRemvca0Pj52fvePJ6nYQbRBfbHz7g0ltzzULD2sAIlmuBKAsKNPfDjRUDH/xw4qvYDrhJCo41yBm0G2HY2gOgs7+lwPo+/+SfSZy9xIlmI05B1UJ+/ImysVuL0VO6h06jvEvN2YqAjPe9olb+aox4LsoDeSJrr5Od3Nb3o7YceaZTDoIHauoQZo7PAtnq9WTv+yqb0DOk35Zis47OgqSx/SvnUSkR1k7Ox933Bz8w1TXeygynsHERVc6CmMdG8VB65/5gZVzw4SnWcrwI7RHAQ7yLshKVfawuyIq7PULOlnC0XU4WUY7a4D7OiKHd7ROjFbdv52P3bAx9wFVjXkDB529L/ZkeJt1zJh7TbDYoFnv4PM8GqfOYLaWc7CYkf/SU3jM9xzlqSjgR2VZ/iw+3fDk+5KxB393Hw0gvbCsKNy8h80DxN95iHgGW2Bc6VxPckLVHCD8x3YURgf6R5YZOyDGd3Ze6sBwY7e8g7PaAvsShgN7Ki/35GxHWFQzZLojbUh1f3MQVGHHVR/7+D2H9xIkCwwzJD+pvrgdt+EVSd20JqV3Dz0mbGDFizjEbeWJup1MuS8VbTAzW+NIwk7KoNj21I/aV84KvMNhjDOd9YHO4b43UEaMu/+bFsgY0crGW+KCyaSjnPEJMzIjg0hgh20crNjzzuaGXs7TSFj9V+BHf1PcpWFu3/sd1CfuxLRZ1Jy9d8rFhvOpFOh2E13M0hQ/h/Ufy/03Vzv4FM1fMSdHM97f0f2N5LULLl3JYYkXQXc/UPY0dAK4O6f6DU8485x0JsKahbsqLnfsVVtn7p8K/yZ3VdK5dZwI4wd9jv63+8IPVaUNEvfOUnj7kl0voN64106KoXeolDySS12kFy6ApVOFKE7WkvMjex5abGbASNmZvSZlGIkxQ7KuobnrcNzFUQlb1Fo9lk4dmBH/Tq85GcOnYeNj8a2fxd2NDEVU6zhGXclOlhXsIOKRl66viG+u1p1FnbQCDs2zKIL93bdc35nv4MqxIf3ykJX2iqVResxbDJ3k6Jn7FeAHdhBPZf3xZ7Rts+OXPjwHi187GUNb3+/I+nuj7yjw82O9vuzJ2UHhaYz2NFhfCS6oQc7kuIDO7CjuUQsaLa0fAfX6bS0zWwXOyrPlsG9wQWX2XT9qPSypsSVRYGVNh07Cji3T3/sUFm0Nckbf/pb7K6D0HVl2OjAMXZgR59reMnRCAqPlutZ7Ki835FidzDprUIZz5UmWrGwo9vkP9FsSVdZDJlP92EHWWmrfeYyVIp+99d+R/qCJdFb57l4l5r+7d9Fhh09L4+N867ATkre58oRN7BgB3z4b6//FxUoWDb82BGMxo7e5k/GvnDpxrnAu78RtvKODvc7UqzhHVQW3v3FDirNjmLvWWS5+DMjO9QsVAEfJc/C7vzd3yyjih1N4L/ZfsXYYVHBjna/yHRdVLK0FJAdhJpjRxPx4StIN84Zz+DZ7xDTXa20Gcc51Nldx1RhhuddaXONhswRO6y0nc/DRHcdREeFmoWwo7m0MfQCAXkHjcfHkOQ9i7iVVv6fdDSwo2Z85Lpz0ErbBzs23tY1n7GDWsgcsYOqsSPjqTPfYMksDDs6WbW8o5U6O2j/di/7HVSNHXnfW4nLDhLd7nVixfKMlmIzmriYLvY6f5bKonAvC3lH+oI570OWLLMldQ+tZp2xozI4xHSuzi9J9yYiPjZ2YAftAh/OpGNHPzsp5bODPXdviIoH87nKuOcCR9w83Ny5QE9JMqCdfqM6TmfelUjxrhN2KMK7ZYd6NnScsQM7ut3vCF3DsQM74MMajh3YYbbYHSzFjqQ3sNjv6HCSG5OMa/ieT+gIXGXFjhi952oIO7CjWsZLoewocCbFuVL4WGDb/iueSQ9x6TiHHV3td0T3Kzix8Dbl7FwpdvgWG8o7Rn8TcbdQ+8cxQmdNaM2CHdhROpfGjhNDHbeTErrZYb8DPmpW+HE9FhJ1b9jnfUXY0cRmh68gVwVXLO/ADio0T1CpDDuis5gCfwt2UM10KYVz6jqx5QIZOxraO2h8pc0V2UPMk9qM+V3Q3jN2dJJLR59oyNulRX43xBzAw47e6vB0qe+Q895g+R12dBV5JRfDFPcGb+6cN7+z32G/o0LG2w2jUyRKxTaAsINGwi7RLXsZJ2HS/G7b8cGOntkxbNpjOSL/L1CzFADTPrtkYEf9VWXnHVgLD3ib8xA7qP6qlatLdjf7HXH7u/Y7KOuqFZcrpX5mke50X9QImM/Y0UKuFOosNrCjwzq8/XmYtKdkxqsMsYO6ijw9JafANOTpz4IdVGceZuwpGT3OeixgR+WaJcUMVxtmZ8e2uZIIayI7oKQVXIozeEGfGTuwo7lcKUvHiZ3XWdjRGz5SH+7OknfIlbCjlQU849OQFFlYouygfE9J+x1ULktXxLm/Azuwo6FcyZ0jidNnA1F9+dphll4YpllGo8CNBGqW9AHthp7UFVzEudLQnpJTf8COrOwYmn+Pdsh590+u8x3pnLGjE3YU2KXvoDZsn/7YQUUrT+opc4yLjW1bhWMHVctoUudKkjvsMMP3NSxCBTvSR/NomkoRlcXOYyNoRcGOatF8+ylDaCxuG9NBB8M2dx6C+7+fmO1ZYgM7ErMjNLgjnnRue9QqzjkOH8VGo8Cs9Jwld94RhIyg6ZeLHXFnUkqOBnZQbHzEbaCkzjuKfYPYQfIO7NgFO+x35GNHgSepBd5zbfx8R+g437Ha3LbMaGz2gc3qjlFlHChwITQQRIQdRIQdRIQdRIQdRIQd2LH5gBL1Iuwoxw7OnPfgjB3igzNn7MAOzpyxAzs4c8YO7ODMGTtI5HHmjB3lv8W3b69//fXp69ePX716+Le/HV6+fPDLL1fX10/evn3TrPP179dPXz59/P3jh39+ePjT4cE3D66+vXry1ydvfnuzw9HI6Pz79fXLp0+/f/z4zw8f/ulw+ObBg2+vrv765Mlvb95gRw52/POfL169enQMi/s/x3D5xz+eN+j84ucXj/7y6IiM+z9HlDz/+/NdjUZG559fvPjLo0djX+DhiJK/P3+OHa2z47iAjEbG7Z/jv9OU8zG5GKXG7Z/jv7OT0cjofEwuzn2Bh+O/gx3tsuO4qpwNjnc/UytMeedjxnEWHO9+prKPnkYjo/Mx45j3BR6mso+U7AjtYDLa5Xi0NcbMX57+nMc69nY6+vXXh48/Pnzwwc3PZ58dvvvuboL673+/ru58/fv1VKkyWry8/tfrjkcjo/Pv19dTpcpo8fKv1697YMf9Sze3vYDzBJhGG3ae/uXZsf7116e3I+DDD28+wFdfHb788uYPH300Kzst7Pz05dOZ4DhRuXQzGhmdXz59uuQLHK9cemPH/ZX/fi+cqf+u0auAN8TE6C9fv348moL++OPNh3z//bu//+WXq+rOj79/PBJf7zQWelffXnU8Ghmdv3/8eBE7vr266pwdU7+c+vPSgiiCHe8eud35+eGHwyef3HzUL764+49evnxQ3fnd49j57HjwzYOORyOj87vHsfN/vnnwID07zs7k+fN8KTtGuTO15TF/v2N0Yfn00xuTzz8f3xWr7jxOjdu6F30dj0ZG5/t0eHTmCzz0wI771weM1ixbseM2DkZb+0XkHe+9d2P+008jwXHhqrWJc+G8o/HRyOgs7zhcsoW5KDvYpDxZVNNO/VxeLV/uXH6/o+XRyOi8u/2O0YxgCiKb1yxlnrO8+3mn+aeACjsXe86SYjQyOu/uOctZdoyWElvVLGXOd5yOj0tOB2zoXOx8R4rRyOi80/MdeeVcaa+j4VwpdtRhx+B9lvyj4X0W7KjDjuG/70o+nH5X8lmDzsfsY/yZyx+lyrNXz3Y1Ghmdj9nH1DOX4+9fPVvpjB1F2TFM39EwWsc24jx1f8foHkf3o5HReer+jtE9DuxolB2cOffhjB3igzNn7MAOzpyxAzs4c8YO7ODMGTtI5HHmjB0RY03Uk7BD3sGZs7wDOzhzxg7s4MwZO0jkccYOEh+cOWMHdnDmjB252RHXU55zGee4bvVxn3nqPdrf3rzBjhzsiOspz7mMc1y3+rjP/POLF1OXDx5RMnVjGHY0xI64O7g4l3HOeD+be8PSsyPu7k/OZZwz3gvb1X2lM4+7lp/hM69EP/v5C985zrmMc1y3+rjP3Ns96ScaoxTm19THiOhHG9frhHMZ57hu9XGfubf+LKcn7VR3+2Gs0/2ifGHU8xJ2LOrPEtdjjXMZ57hu9XGfube+cCeaSI/+8myX6RX5wuXsWNqSMq63K+cyznHd6uM+c2/9aOfsd8zv9nb2lysQdrp55Tp2xPWU51zGOa5bfdxnvk+HR2eMD62z42zNsogdoySac/XA1CbI6eaV8g55x7bd6uUdUTXL/Lxj0ROmxYnDjDrI3sEO9zsu71Zvv2MzdizNO8rvd6xgh2cWnT1n2bBbvecsG+x3rOtuv6JV/XDB+Y517HBWIrtzXLd65zvozFg7o5nd2blS7KjDjsG7Ifmdvc+CHXXYMUT2lOdcxjmuW33cZz5mH1PPXI6/f/VspTN2FGXHENlTnnMZ57hu9XGfeer+jtE9DuxolB2cOffhjB3igzNn7MAOzpyxAzs4c8YO7ODMGTtI5HHmjB0RY03Uk7BD3sGZs7wDOzhzxg7s4MwZO0jkccYOEh+cOWMHdnDmjB252ZGr1/k7xXV+z9hTnjN2VGBHul7nQ2Tn94w95TljRwV2ZLwbKu6mrIx3cHHGjgrsyHgnZdwNnRnv/uRcgh3zu7ee+P+u+FSnm07e/W9e29d2ZlO7O9Vmuruw4zq/Z+wpz7kcO0a7q0XvGM/hzoV9Xs42aummB0dc5/eMPeU5N8GOE/3ub/+jO9N1zvo/M+8oz46Mvb/iOr9n7CnPuWjNcv9/h3n97hf909PIaIQdGXuOxnV+z9hTnnN9dqyYuism9uriZZjXlW7pfkfGXudxnd8z9pTn3AQ7Zva7n5OqTPnEsWPneccmnd8z9pTn3G7NcknesWK/Y3Uva/sdl3d+z9hTnnPpZ7RLdzHK1CynHyF7zjL6NGTDzu8Ze8pzrs+OYUa/+zmpyurnLFP3qTnfcfoUxoad3zP2lOdciB17lnOldZ2d/izjjB3l2DF4n6WUs7dOyjhjRzl2DAl7nQ+Rnd8z9pTnjB112DFk63X+fzsUQZ3fM/aU54wdddjBmXMfztghPjhzxg7s4MwZO7CDM2fswA7OnLGDRB5nztgRMdZEPQk75B2cOcs7sIMzZ+zADs6csYNEHmfsIPHBmTN2YAdnztiRmx0Ze8pzvq24bvVTb0L/9qZFZ+woyo6MPeU531Zct/qfX7yYuj7yOOGn7nyr6Iwd5diR8Q4uzreV8ea3OGfsKMSOjHd/cr6TcaS7cTbOuQI7Tvc3KPYZLr8SfdE96Rl7ynO+s8eR7qb7OOdq7DjR5rowvFa3YlnaYyFjT3nOt5Wxw06cc4vsmGq5MtVi7myDqGFeW8lodmTsKc/5tjJ29otzrlmzLGo3ObOVXDF2nOjOPXTUU57zbWXsKBznnIYdZ4lw51+e6qE9p3gJYkfGnvKc/+eXYT3l78/hR2eM6ztjxxp2LO2SfWI9bLynPGd5B3acn+GL2HH6WpRuespztt/R6DPaS/rdr/jz/OfEM1veX/KcJUVPec6es6Rhx3Cytf3Uw445GcTo/+vsI5648x0pespzdr5jcK60pJzR7NXZuVLsqMOOwbsh+Z29z4Idddgx5Owpz/lO9hHUrf6YI0w9GTn+/tWz5pyxoyg7hpw95Tnf2fsI6lY/dcvG6E5EdWfsKM0Ozpz7cMYO8cGZM3ZgB2fO2IEdnDljB3Zw5owdJPI4c8aOiLEm6knYIe/gzFnegR2cOWMHdnDmjB0k8jhjB4kPzpyxAzs4c8aO3OyI66LOmfOUpt4qfvv2DXbkYEdcF3XOnKf0x20mj6ZvM3mOHa2zI+7WKc6cJ3OZsFvUsKMQO+Juu+TMufztrXPZMf+Y6lbTb9HB2KXbRYuuRD8sb5Y1WscG3bLNmfMw79b4r78+fPzx4YMPbn4+++zw3Xfrb41fxo5i+7pL/5al7FjaBWb0v30pO+K6e3DmPMzrVvPhhzdx+9VXhy+/vPnDRx+t71azGTtONK8fbUN9ep0/+/dONXA522xlJndGu8zd/09bxI64rmKcOQ8Lu+T9+OON9/vvr++Stw071jWvX9qnfk7KsNR85v9lk5olrpspZ87Dku68P/xw+OSTG+8vvljfnXf7/Y75jSBbYMf87nOXsyOuizpnzlPOo0nHp5/eWH7++fiOaWzecaKOuIQdZxtEDhPtIFOww3rIuZG84733box/+mkEHFF5x6JZVyDvmJOADLO7xkazQx3OuZ39jqmfEvsdc/Y4Wq5Zzm79bs4O+/+cqz9nOd3Zu+ZzlkV5R8XnLFMbN853cO77fMdpdkSd76D5ct6Rs3OltCU7Bu9ZcPY+C61jxxDZRZ0z5yn98R7tw+n3aFc6Y0dRdgyRXdQ5c57S1P0do3sc2NEoOzhz7sMZO8QHZ87YgR2cOWMHdnDmjB3YwZkzdpDI48wZOyLGmqgnYQcRBSyTBoKIsIOIsIOIsIOIsIOIsAM7iAg7iKgcO4iIluo/jB3UleChsXAAAAAASUVORK5CYII=</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-08-07 15:35:44 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2012-08-07 15:35:44 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2012-08-07 15:35:44 +0200" MODIFIED_BY="[Empty name]">Keywords</TITLE>
<APPENDIX_BODY MODIFIED="2012-08-07 15:35:06 +0200" MODIFIED_BY="[Empty name]">
<P>{acth} OR {adrenal cortex hormone\*} OR {corticosteroids} OR {glucocorticoids} OR {methylprednisolone} OR {prednisolone} OR {prednisone} OR {steroid\*} AND {oral} OR {peroral} OR {oral administration} OR {intravenous}</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 trials included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;5 trials included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;42 of full-text articles and raw data from one unpublised trial assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;115 of records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;709 of records identified through database searching &lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;11 additional records identified through other sources &lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;73 of records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;17 of full-text articles and clinicaltrials.gov listints excluded, with reasons; &lt;/p&gt;&lt;p&gt;20 excluded without reasons provided as clearly ineligible&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>